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83  ABSTRACT
High quality of platelet analytics requires specialized knowledge and skills. It was 
applied to analyze platelet activation and aggregation responses in a prospective 
controlled study of patients with Finnish type of amyloidosis. The 20 patients with 
AGel amyloidosis displayed a delayed and more profound platelet shape change 
than healthy siblings and healthy volunteers, which may be related to altered 
fragmentation of mutated gelsolin during platelet activation. Alterations in platelet 
shape change have not been reported in association with platelet disorders. In the 
rare Bernard-Soulier syndrome with Asn45Ser mutation of GPIX, the diagnostic 
defect in the expression of GPIb-IX-V complex was characterized in seven Finnish 
patients, also an internationally exceptionally large patient series. The Bernard-
Soulier syndrome may be underdiagnosed as the typically large platelets also 
detected in the present study may not always be of giant size. When measuring 
thrombopoietin in serial samples of amniotic fl uid and cord blood of 15 pregnant 
women with confi rmed or suspected fetal alloimmune thrombocytopenia, the lower 
limit of detection could be extended. The results suggested that thrombopoietin 
was present in amniotic fl uid, and that its concentration decreased during the 
last weeks of pregnancy and was not associated with that of cord blood plasma 
in these patients. The application of various non-invasive means for diagnosing 
thrombocytopenia (TP) revealed that techniques for estimating the proportion of 
young, i.e. large platelets, such as direct measurement of reticulated platelets 
and the mean platelet volume, would be useful for evaluating platelet kinetics 
in a given patient. Similar approaches have been applied to new principles for 
characterizing of platelet kinetics, e.g. by measuring immature platelet fraction 
and large cell ratio. Due to different kinetics between thrombopoietin and increase 
of young platelets in circulation, these measurements may have most predictive 
value when measured from simultaneous samples. Platelet autoantibodies were 
present not only in isolated autoimmune TP but also in patients with several 
different diagnoses without TP where disappearance of platelets might be 
compensated by increased production. The autoantibodies may also persist after 
TP has been cured. Simultaneous demonstration of increased young platelets (or 
increased mean platelet volume) in peripheral blood and the presence of platelet 
associated IgG specifi cities to major glycoproteins (GPIb-IX and GPIIb-IIIa) can be 
considered diagnostic for autoimmune TP. The role of increased platelet associated 
IgG without apparent GP-specifi city even when related to platelet size remained 
unclear. Lastly, measurement of a soluble marker as a sign of thrombin activation 
and proceeding deterioration of platelet components was applied to analyze 
the alterations under several stress factors (storage, transportation and lack of 
continuous shaking under controlled conditions) of platelet products. The GPV 
measured as a soluble factor in platelet storage medium showed good correlation 
with an array of other measurements commonly applied in platelet quality control. 
The benefi ts of measuring soluble analyte in a quantitative assay were evident 
and were taken into consideration in selecting assays for the current studies of 
platelet components. Clinical studies to measure the transfusion response of 
platelet components characterized for their soluble GPV are expected to show the 
signifi cance of soluble GPV.
94  INTRODUCTION
Platelets are small (1-3 µm) anucleate cells that adhere to damaged blood vessels 
and effect primary haemostasis. Platelets are released by mature megakaryocytes 
and circulate in blood with an average lifespan of nine days. Although the reference 
range is broad (150-360 x 109/l 1; 177-406 x 109/l 2), an individual’s platelet 
count is maintained within a narrower range3. This requires a constant balance 
of thrombopoiesis with platelet senescence and consumption. The haematopoietic 
growth factor, thrombopoietin (TPO), is the primary regulator of megacaryocyte 
growth and platelet number4. The precise mechanism of platelet formation and 
release in vivo remains a continuous area of study.
 Blood platelets play critical roles in haemostasis, providing rapid protection against 
bleeding and catalyzing slower formation of stable blood clots via the coagulation 
cascade. They are also involved in protection from infection by phagocytosis of 
pathogens and by secreting chemokines that attract leukocytes. Platelet function 
is commonly assessed by platelet count, bleeding time, and platelet aggregation 
or activation. However, defi ning and measuring in vivo platelet function remains a 
challenge.
Platelets are capable of responding to changes in blood fl ow and to the sub 
endothelial matrix of vessels in addition to maintaining the integrity of the 
vasculature. Platelets can adhere to the vessel wall, aggregate with other platelets, 
and release the contents of their cytoplasmic granules. These events may result in 
the recruitment of more platelets and the initiation of an infl ammatory response 
and of the coagulation cascade5,6.
A primary and critical step in platelet attachment to injured vascular endothelium 
is the formation of reversible bonds between the platelet GP receptor Ibα and the 
A1 domain of von Willebrand factor (vWF). Due to the platelet’s discoid shape, 
hydrodynamic compressive forces may play an important role in initiating tether 
bond formation7. 
Upon activation, platelets change their morphology from a disc to a small cell 
with many active extensions. These changes include release of granule contents, 
change of expression in levels of major GPs, solubilization of membrane, and 
formation of microparticles8. The cytoplasm is rich in actin and myosin, which 
participate in the shape change and retraction of the clot. 
Furthermore, activated platelets release their granules, thus providing the 
microenvironment with growth factors that contribute to the migration and 
proliferation of smooth muscle cells and macrophages. Platelets may not distinguish 
between a damaged vessel wall and the atherosclerotic disruption of a coronary 
artery.
Membrane GPIIb-IIIa, Ia-IIa, and Ibα of the GPIb-IX-V complex bind fi brinogen, 
collagens, and vWF, respectively, and are critical for the initial interaction of 
circulating platelets with the injured vessel wall under high shear conditions.
Platelets function also as a necessary mediator in atherosclerosis. The adhesion 
of platelets to vWF is mediated by the GPIb-IX-V surface receptor on platelets. 
After adhesion, platelets are exposed to the microenvironment of dysfunctional 
endothelial cells. The microenvironment provides platelets with agonists, which 
stimulate platelet aggregation. The aggregated platelets promote the formation of 
a thrombus which may further exacerbate the infl ammatory reaction. 
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5 REVIEW OF THE LITERATURE
5.1 Platelet life span
Platelets are lost from circulation by two mechanisms: either by senescence or by 
random removal in endothelial supportive functions of a fi xed fraction of platelets 
amounting to 7.1x109/l/d. At platelet counts above 100x109/l, this fi xed platelet 
loss is in balance with platelet production. It has also been shown that haemostasis 
may be maintained with platelets at approximately 7.1x109/l. Senescent platelets 
are removed primarily by macrophages in the spleen, although the larger blood 
fl ow through the liver allows severely damaged platelets to be removed more 
quickly by hepatic macrophages9. It is assumed that when aging, platelets contain 
decreased levels of sialic acid10 and they accumulate surface IgG11.
Normally, platelets circulate in blood with an average lifespan of 7-
10 days. Platelet lifespan is decreased in numerous pathological conditions 
including autoimmune thrombocytopenic purpura (ITP), neonatal alloimmune 
thrombocytopenia (NAIT), drug-induced thrombocytopenia, thrombotic 
thrombocytopenic purpura, post transfusion purpura, disseminated intravascular 
coagulation, diabetes mellitus, and coronary atherosclerosis. Platelet kinetic 
studies have shown that in ITP patients, a shortened mean platelet life may be 
associated with a decreased platelet production rate12. In ITP, platelet lifespan can 
be as short as minutes13. In Bernard-Soulier syndrome (BSS) patients, TP is most 
likely due to increased clearance, although defects in production are possible14,15.
Autologous platelet turnover studies in the 1970s showed that most ITP 
patients have either normal or reduced platelet turnover rather than increased 
turnover, as would be expected if platelet destruction were the only pathogenetic 
mechanism16. More recently, in vitro culture studies have shown that some ITP 
plasmas suppress both megakaryocytopoiesis and thrombopoiesis in both adult 
and pediatric ITP. In view of these fi ndings, both increased platelet destruction and 
suppression of platelet production seem likely to be involved in the pathogenesis 
of immunological TP17.  
5.2 Structure of platelets
Platelets are the smallest of blood cells. Despite their unique origin as anucleated 
fragments of megakaryocytes, they may contain many structural, metabolic, and 
signaling components of nucleated cells.
Platelets are released from the ends of megakaryocyte proplatelets as oval 
discs with average size of 2 µm. Younger platelets have greater functional ability10. 
Each megakaryocyte forms 103 platelets and 1011 platelets are replenished daily9. 
The surface of the disc has been described as featureless and lacking protrusions, 
except for membrane invaginations, which are the entrances into an elaborate 
conduit system of internal membranes called the open canalicular system (OCS). 
These entrances allow small molecules to enter but restrict the entry of larger 
proteins such as antibodies18. 
Platelets have membrane skeletons that are self-assemblies of elongated 
spectrin strands. Strands interconnect through their binding to actin fi laments, 
as an actin binding site is posited on each molecular end of spectrin. Most of the 
platelet fi lamin is in complex with GPIbα19,20, and it aligns the GPIb-IX-V complexes 
on the surface of the platelet over the underlying fi laments (Figure 1).
Actin is the most abundant of all the platelet proteins, at about 2 million copies 
per platelet. Of these molecules, 800 000 assemble to form 2000-5000 linear actin 
polymers in the resting cell21,22 (Section 5.4, Platelet shape change).
11
Platelets share many receptors, the most important being GPIb-IX-V complex, 
GPIIb-IIIa, and P-selectin (CD62P; Figure 1). The complexity of the platelet 
membrane GPs and their crucial roles in platelet function were fi rst appreciated 
in the 1970s23,24. It is now known that platelet membrane GPs act as receptors 
for subendothelial ligands or plasma factors, are responsible for interactions 
between leucocytes and platelets, and transduce signals both inward and outward, 
mediating platelet activation. 
The possible role of platelet receptors or their polymorphic variants in diseases 
such as cardiovascular disorders has initiated intensive research25. The platelet 
ADP receptors are involved in the initiation of platelet activation (P2Y1)  and in 
shape change and aggregation responses to ADP (P2Y12)
26. Platelet receptors 
may be defi cient in some disorders, or targets for antibodies in other pathological 
conditions. 
 
 
The resting cell contains e.g. numerous α-granules, a few dense granules, 
mitochondria, and membrane-lined tunnels that correspond to the OCS. α-granules 
are the larger and have GP receptors, which promote adhesion between platelets 
and the matrix. Adhesive components within the α-granules include the matrix 
adhesive proteins, e.g. fi brinogen, fi bronectin, thrombospondin, vitronectin, and 
vWf. The dense granules are smaller and they carry the soluble activating agents 
ADP and serotonin as well as divalent cations. CD62P is stored in the membranes 
of α-granules as well as a portion of the major platelet adherence receptors (GPIb-
IX-V and GPIIb-IIIa)5. A small amount of the total platelet CD62P is stored in the 
membrane of the dense granules. Platelets are also able to interact with endothelial 
CD62P27.
On activation, platelets change from the normal disc shape to compact 
sphere with long dendritic extensions facilitating adhesion. They attach, change 
shape, and spread over the damaged area. In addition, secretion is initiated, 
thromboxane is released, and surface integrins are activated, especially GPIIb-
Figure 1. Selected platelet membrane GPs and receptors. 
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IIIa28. In platelet activation the number of GPIb is reduced but the number of 
GPIIb-IIIa is increased29,30. In addition, ADP is released from dense granules.
GPIb-IX-V 
The GPIb-IX-V complex on the platelet surface consists of four polypeptide chains 
designated GPIbα (CD42b), GPIbβ (CD42c), GPIX (CD42a), and GPV (CD42d)31. 
GPIbα, consists of 610 amino acids (MW 150 000)32, GPIbβ of 181 (MW 25 000)33, 
GPIX of 160 (MW 22 000)34, and GPV of 544 amino acids (MW 82 000)35. 
Complete expression of GPIb-IX-V requires three subunits of the complex. 
Absence of any one of the polypeptides of the complex, except for GPV, leads 
to reduced expression of the complex36. Expression of the GPIb-IX-V complex is 
limited to megakaryocytes and platelets. In BSS, GPIb and GPIX are absent or 
defi cient37. (For BSS, see 5.5).
In normal platelets, the GPs are expressed on the plasma membrane in an 
apparent molar ratio of 2:2:2:1 (approximately 25 000 copies of GPIbα, GPIbβ, 
and GPIX, and 12 500 of GPV)31,38. It has been shown that GPIb is homogeneously 
distributed on external and internal membranes of resting platelets39. 
The vWF binding domain is located at the N-terminus of GPIbα40. The GPIbα 
chain also binds a number of other ligands, including thrombin41,42 and CD62P27. 
The vWF-GPIb interaction stimulates actin polymerization and cytoskeletal 
reorganization in rolling platelets43. GPIb-IX-V/vWF interaction also has an 
important role in platelet thrombus growth44. 
CD62P has been shown to interact with the α-chain of GPIb, suggesting that 
GPIb-IX-V could be a counter-receptor for CD62P45. 
The major physiological role of the GPIb-IX-V complex is to mediate initial 
adhesion of circulating platelets to vWf in the subendothelial matrix46. The GPIb-
IX-V complex mediates signal transduction, and is involved in thrombopoiesis31,47. 
GPV binds to collagen and appears to be required for normal platelet responses 
to this agonist48,49. GPV is cleaved from the platelet surface during activation by 
thrombin (soluble GPV, see Soluble activation markers, Section 5.2). It is required 
for thrombin binding, possibly through an interaction with GPIbα.
In alloimmunization, GPIb-IX-V complex is not as immunogenic as GPIIb-IIIa50, 
although polymorphic sites (GPIbα and GPV51-53), and a length polymorphism 
have been described in it54,55. GPIb and GPV can both act as autoantigens in ITP 
patients56,57. In patients with quinidine-induced thrombocytopenic purpura, those 
with GPIb-IX-specifi c antibodies recovered faster than patients with GPIIb-IIIa-
specifi c antibodies58.
GPIIb-IIIa 
The subunits GPIIb and GPIIIa are noncovalently associated.  GPIIb consists of 
1008 amino acids (MW 148 000) and GPIIIa of 762 amino acids (MW 95 000). Like 
all other integrins, GPIIb-IIIa is a Ca2+-dependent and αβ type I transmembrane 
heterodimer, each subunit consisting of a relatively large extra-cellular domain 
and a short cytoplasmic tail.  Resting platelets contain about 80000 copies of 
GPIIb-IIIa on the surface, with additional pools in the membranes of α-granules 
and the OCS59. A direct relationship has been observed between the size of the 
platelets and the number of GPIIb-IIIa, and also with the Ib complex antigens per 
platelet60.
Fibrinogen binds to activated GPIIb-IIIa complexes and is thought to mediate 
aggregation by forming bridges that link platelets together61,62. GPIIb-IIIa also acts 
as a receptor for fi bronectin and vitronectin. GPIIb-IIIa is capable of transducing 
signals both from inside and outside of the cell. To mediate these functions, GPIIb-
IIIa interacts with intracellular and transmembrane proteins, such as α-actinin and 
myosin63. 
13
The major platelet GPIIb-IIIa is the main receptor involved in aggregation and 
spreading on extracellular matrix. Platelet thrombi are formed by sequential steps, 
including tethering of circulating platelets to the vascular injury site, fi rm adhesion 
of the tethered platelets, and accumulation of additional platelets onto the surface 
of the adherent platelets, leading to formation of large platelet aggregates64,65.
Null or loss-of mutations of the GPIIIa gene result in the inherited bleeding 
disorder Glanzman thrombasthenia66,67.
GPIIb-IIIa complex has been recognized to be the most immunogenic of 
the platelet GPs, carrying most of the known alloantigenes. Target antigens of 
circulating platelet autoantibodies have also most frequently been determined 
on the platelet GPIIb-IIIa68-70. Measurement of the GP-specifi c autoantibodies, 
especially GPIIb-IIIa-specifi c autoantibodies, remains the gold standard in the 
diagnosis of immune TP71,72. 
GPIa-IIa and GPVI
GPIa-IIa (MW 293 000) is well established as a collagen adhesion receptor. 
There are 2000-4000 GPIa-IIa copies per platelet. Its expression level has been 
presented to relate to the incidence of cardiovascular desease73.  
GPVI is another collagen receptor and essential in signal transduction for 
collagen-induced platelet activation74. GPVI is a type I transmembrane protein 
(MW 62 000) and is noncovalently associated with the Fc receptor γ chain, which 
is required for optimal activity of GPVI75 76. Recent studies have shown that GPIb-
IX-V and GPVI are physically linked on platelets and seem to act in concert, as the 
presence of both receptors facilitates stable platelet aggregation77.
In thrombus formation, after the initial tether of GPIb-IX-V to vWF, GPIa-IIa-
receptor binds collagen of type I and III. The fi rst layer of adhering platelets is in 
direct contact with collagen and becomes activated via GPVI74. 
The number of receptors differs markedly between individuals. Type I collagen 
adhesion varies over a 20-fold range and type III collagen adhesion over a 5-fold 
range78. Increased receptor density has been associated with myocardial infarction 
and stroke79. 
 
CD62P and CD63
The CD62P-antigen, a platelet α-granule protein (Figure 1, MW 140 000), 
is redistributed to the plasma membrane during platelet activation and 
degranulation80,81. Surface-expressed CD62P mediates the binding of activated 
platelets to neutrophils and monocytes involved in early infl ammatory reactions82,83. 
There are 13400±3000 CD62P molecules on each activated platelet84. In addition, 
the dense granule membrane contains CD62P85.
The proportion of activated platelets has been suggested to predict platelet 
quality in platelet concentrates. The expression of CD62P has been shown to 
have inverse correlation with the platelet count increment, and the recovery of 
platelets86-92. In an animal model the circulating degranulated platelets lost surface 
CD62P but still continued to circulate in vivo93. 
CD63 (MW 40 000) is present in platelet lysosomes94 and dense granules95. It is 
expressed on the membrane after exocytosis. Although CD63 has been associated 
with integrins96, very little is known about its function. It has been suggested 
to infl uence platelet spreading97. CD63 appears to be involved in an endosomal-
lysosomal degradative pathway. Lysosomal secretion can be elicited in vitro with 
such agonists as thrombin or collagen98. 
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Soluble activation markers
In addition to changes observed in expression of several surface markers 
during platelet activation, soluble activation markers, e.g. soluble CD62P99, 
GPIb, glycogalicin (the major and extra membranous portion of GPIbα)100,101, 
β-thromboglobulin102, and soluble GPV (sGPV)103 are released into the storage 
medium.
The glycocalicin concentration in plasma has been suggested to refl ect platelet 
turnover and platelet membrane injury in vivo104. Soluble GPV concentrations are 
signifi cantly increased in platelet activation during storage of platelet concentrate 
(PC). Azorsa et al compared the surface expression of GPV and soluble GPV from 
apheresis concentrates during storage of 13 days, and the removal of GPV from 
platelet surface correlated inversely with the increase of soluble GPV103. In the 
same study, correlation of soluble GPV with CD62P was good. The results have not 
been confi rmed from other laboratories.
The soluble GPV measurement has also been used in arterial diseases as an 
activation marker, such as during the acute clinical course of unstable angina 
pectoris. Increased soluble GPV has also been reported in patients with acute 
ischemic stroke105,106. 
Soluble markers have been applied in separate studies concerning PCs and 
have usually been compared only with platelet membrane activation markers. The 
clinical signifi cance of the different soluble markers remains unclear. 
5.3 Markers of platelet production 
Platelet count and size 
Platelet counts within the reference range refl ect platelet production which is in 
balance with disappearance.  An accurate platelet count may be obtained in the 
normal reference range. (See also Cell counters, Chapter 5.9). 
Normal circulating platelets display a log normal size distribution pattern. 
The platelet size histogram shows evidence of heterogeneity even in healthy 
subjects. Age, gender, and the number of circulating platelets infl uence the size 
distribution107-109. 
Circulating platelets may be considered a pool of platelets with different age 
and size. Platelet size measured as mean platelet volume (MPV) can refl ect either 
the level of platelet stimulation, or rate of platelet production or senescence9. 
The controversy over whether platelets change volume or density in the 
circulation is still not clearly resolved. Although the relationship between platelet 
number and size and megakaryocyte number, size and ploidy has been described110, 
the factors that regulate this interaction are still poorly understood108. It is known 
that megakaryocytes of low ploidy number produce large platelets with more 
organelles and with less OCS than those platelets produced by megakaryocytes 
of high ploidy number111. Young platelets have been shown to be larger and 
hemostatically more active than older ones112. Large platelets are more sensitive 
to ADP and aggregate more rapidly than smaller platelets. It has been shown that 
large platelets have a longer mean lifespan than small platelets10. 
Blood platelets have been found to vary in size in various hematological 
disorders, and in most cases there is shortened platelet survival time. In Wiskott-
Aldrich syndrome, originally described in 1937, MPV is characteristically reduced113-
115. In sepsis, too116, small platelets have been found. Extra large platelets appear 
in most BSS variants14,15, Gray platelet syndrome117, and May-Hegglin anomaly118.
MPV has been shown to be increased by 20-30% in patients with ITP (normal 
or hyper-plastic marrow)17,119-121. Platelet populations in ITP have been shown to 
have increased size heterogeneity as refl ected by an increased percentage of 
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microthrombocytes and/or platelet fragments, and an increased percentage of 
megathrombocytes122. 
Platelets have been reported to be larger in type 2 diabetic patients than in 
normal individuals (10.6 and 9.1 fl , respectively)123,124, after myocardial infarction 
(12.1 and 8.3 fl , respectively)125, and in severe pre-eclampsia126. In ischemic heart 
disease, the patients’ MPV after an exercise stress test increased signifi cantly 
compared to the control group127.
An abnormal increase in platelet volume and low platelet counts found in 
patients with coronary heart disease may serve as indicators for a prethrombotic 
state and the risk of myocardial infarction128,129. MPV is associated with a poor 
outcome in acute ischemic cerebrovascular events, independent of other clinical 
parameters130.
Electronic particle counters may give a falsely low platelet count and lead 
to misdiagnoses (pseudothrombocytopenia) if the platelet counting is not 
appropriately controlled131. Proper method standardization and the development 
of more consistent specimen handling conditions may allow the MPV to have 
broader clinical application in detecting and monitoring vascular disorders108. The 
MPV measured from citrated samples is lower than that measured from an EDTA 
sample, and the size may increase during storage of the sample. Most of the 
increase occurs during the fi rst 1.5 hours but the process continues over the next 
24 h109. In addition, the measurement principle used in the instrument infl uences 
the result and therefore the reference values may differ from each other (Table 
1). 
Table 1. Reference values of MPV.  
In PCs, MPV as an age-dependent parameter has been theoretically suggested 
to be of value in assessing the quality of PCs133. MPV may correlate with pH 
changes138. Particularly, the difference in MPV before and after the addition of 
EDTA to the sample correlated with age and hypotonic shock response (HSR), and 
pH and lactate dehydrogenase measurements139. Platelet distribution width (PDW) 
correlated indirectly with pH and HSR results (R2=0.95 and 0.89, respectively)140. 
The presence of large platelets increased the production of lactic acid and 
accelerated the platelets’ metabolic storage lesion141.  Neither platelet volume nor 
N Reference 
range (fl) 
Anticoagulant Instrument Detection system Reference 
46 7.1-4.9 Citrate Microscope Visual 132
50 4.2-9.0 PRP citrate n.s. Impedance 133
23 8-12 EDTA n.s. n.s. 134
n.s. <10 Citrate n.s. n.s. 131
36 4.5-8.5 
7-13 
Citrate 
EDTA
Coulter Impedance 135
223 7-7.8 n.s. Thrombocytometer Pulse detection 136
80 7.6-10.2 
6.8-10.0 
Citrate 
EDTA
Coulter Technicon Impedance optical 2
21 7-8 PRP n.s. n.s. 107
73 7-10 EDTA Sysmex 2000i Hydrodynamic focusing 137
N=number of healthy adult individuals studied 
n.s. = not specified 
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other platelet indices belong to the quality requirements of platelet products and 
are not recommended quality parameters of PCs for transfusion142.
According to Kaito et al, more attention should be paid to MPV, PDW, and 
platelet large cell ratio (P-LCR) in the diagnosis of TP143. PDW and P-LCR have been 
analyzed from a histogram of platelet size distribution. The distribution width at 
the level of 20% was defi ned as the PDW, and the percentage of platelets with a 
size of more than 12 fl  was defi ned as the P-LCR. 
Reticulated platelets
Reticulated platelets (RP) were fi rst identifi ed by Ingram et al144. They were termed 
“reticulated platelets” because of the analogy with red cell reticulocytes. They 
were reported to be larger and have a higher density and increased ribonucleic 
acid (RNA) content145. RPs have been shown to be unstable and to undergo 
degradation in the circulation within 24 h in animal studies145. The percentage 
of RPs (%RP) could be a useful marker of increased platelet production and/or 
turnover in patients with increased thrombopoiesis, whereas a low %RP in TP 
indicates marrow suppression146.
RPs have been reported to appear in the circulation of plateletpheresis donors 
within 24 hours after donation147. The proportion of RPs and MPV were highest 
on day 2, and persisted above normal levels until day 7. After plateletpheresis, 
platelet counts were higher than could be accounted for by platelets removed 
by apheresis, which suggested stimulation of thrombopoiesis or the release of 
sequestrated platelets. Although whole blood donors manifested no changes in 
platelet counts they had a peak of circulating RPs 2 days after the donation.
Platelet count and RP have been shown to correlate negatively in patients with 
ITP, but they did not correlate in patients with aplastic anemia, liver disease, or 
after chemotherapy148. RP has been shown to be signifi cantly increased in patients 
with ITP, especially in the active phase, while RP was markedly decreased in 
patients with essential thrombocytosis or chronic myelocytic leukemia149. RP and 
large platelets were poorly correlated with platelet-associated IgG (PA-IgG), and 
with plasma thrombopoietin (TPO) levels, but correlated negatively with platelet 
count. 
The percentage of RP platelets during bone marrow recovery differed 
between aplastic patients and control subjects (23.3. and 5.7%, respectively)150. 
In addition, MPV during bone marrow recovery increased in 12 cases of the 18 
patients studied. 
Measurement of young platelets, expressed as the immature platelet fraction 
(IPF), has been used in the laboratory diagnosis of TP due to increased peripheral 
platelet destruction151. An IPF reference range in healthy individuals was established 
as 1.1-6.1%. The most signifi cant increases in IPF values were found in patients 
with autoimmune TP (9.2-33.1%) and acute thrombotic TP (11.2-30.9%). The 
IPF remained stable over two days when blood samples were stored at room 
temperature. It has been suggested that IPF may also have potential in developing 
a more controlled prophylactic platelet transfusion policy152.
The clinical signifi cance of measuring of RPs in thrombocytopenic patients is 
not yet known. Similarly, the role of IPF is unclear.
Thrombopoietin
TPO was fi rst proposed as the primary regulator of platelet production almost 50 
years ago153. The gene for TPO (and megakaryocyte growth and differentiation 
factor, c-mpl ligand) was cloned only within the last decade by four groups154-157. 
It is now appreciated that in addition to its critical role in the development of the 
hematopoietic stem cell into the large mature platelet-producing megakaryocyte4, 
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the growth factor affects multiple aspects of haematopoiesis, including a role in 
stem cell survival, self-renewal and expansion158. 
Several organs and tissues contain TPO messenger RNA; the liver, kidneys, 
smooth muscle, and marrow being the most prominent among them. TPO is produced 
primarily in the liver at a constitutive rate. The plasma TPO level is regulated via 
adsorption and internalization by cells that express the TPO receptor. TPO level is 
inversely correlated with the total counts of both megakaryocytes in bone marrow 
and platelets in circulation and spleen159-161. When platelet production decreases, 
the clearance of TPO is reduced and its plasma concentration increases.
Due to the different circulation kinetics of TPO and platelets, a proportion of ITP 
patients have normal TPO levels162.  
Although knowledge about the usefulness of TPO levels as a diagnostic tool is 
rapidly increasing, TPO levels especially in pediatric patients, amniotic fl uid and 
fetuses have not been studied earlier. TPO could be assumed to function the same 
way as erythropoietin, the regulator of red cell production, which can be measured 
from amniotic fl uid and its concentration correlated with that of umbilical plasma 
erythropoietin163.
5.4 Tests of platelet function
Platelet metabolism during storage
During storage of platelets in concentrates, there are two major metabolic 
pathways: glycolysis, which does not require oxygen, and oxygen consumption 
through the tricarboxylic acid cycle164 (Figure 2).
In glycolysis, one molecule of glucose is converted into two molecules of 
lactic acid. The rates of production of lactic acid and consumption of oxygen are 
essentially the same. Because the production of one lactate molecule fuels the 
regeneration of one ATP molecule and the consumption of one oxygen molecule 
regenerates six ATP molecules, the cell must derive approximately 85% of its ATP 
regeneration from oxygen through the tricarboxylic acid cycle and 15% through 
glycolysis.
Figure 2. Metabolic pathways used by platelets during storage 
in plasma or synthetic media164,165.
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For energy production, platelets use glucose and free fatty acids from plasma 
and e.g., acetate added to the synthetic medium. Almost all glucose used is 
converted through pyruvate to lactate and a hydrogen ion. In storage medium, 
the hydrogen ion is buffered by bicarbonate, which is thereby converted to carbon 
dioxide that can leave the medium through the walls of the container. Very little, 
if any, pyruvate is decarboxylated to acetyl-CoA and carbon dioxide.  Thus, 
storage solutions need to reduce the rate of glycolysis to a minimum and provide 
a mechanism to buffer the hydrogen ion that is produced by glycolysis164. Also the 
amount of plasma should be optimal (30%)166.
Platelet swirling
Normal discoid platelets, when exposed to a light source and gently rotated or 
squeezed, refract light and produce a “swirling” phenomenon that can be identifi ed 
by trained personnel in PCs for transfusion. It was shown already in the 1970s that 
maintenance of normal discoid morphology during storage may be essential for 
maintenance of platelet viability167. According to a multicenter evaluation swirling 
seemed a promising method for large-scale quality control of PCs168. Swirling can 
be scored with levels 1-4 (Table 2).
Quality control of PCs may involve determining the pH level and evaluating 
platelet count, size, and morphology and/or the response to aggregating agents 
and hypotonic shock170. These assays are invasive, require dedicated laboratory 
devices and personnel, and cannot be performed on all PC’s before they are 
released for transfusion. Platelet discoid shape correlates well with in vivo platelet 
viability. Swirling is easily evaluated without any specifi c instrumentation.
A lack of swirling may correlate with a less-than-predicted posttranfusion 
platelet increment 168,171. In a multicenter evaluation of PCs prepared and stored 
under routine conditions, the presence of swirling correlated well with pH values 
associated with adequate platelet in vivo viability, although in 20% of swirling-
negative PCs the absence of swirling was not due to low or high pH171. Aggregometry 
has been used for detection of optical properties of discoid and spherical cells172. 
Differences in transmission between different mixing rates were measured173. 
Neither method has replaced the use of swirling.
Swirling-negative PCs should be investigated further and discarded if they fail 
to meet other standards of quality. 
Platelet shape change 
Platelet shape change is a complex process which depends on the cytoplasmic 
dynamics of the actin polymer174. To spread, the resting platelet must reorganize 
its cytoskeleton and assemble new actin fi laments. The actin fi lament network 
22°C  4°C
4 Excellent 6.8-7.3 1d
3 Good 6.7-6.8 or 7.3-7.5 5 d
2 Fair 6.4-6.7 or >7.5 7-10d
1 Poor <6.3 10-14 d >24h
Typical PC storage
timeLevel Grading pH
Table 2. The quantifi cation of swirling by visual inspection. 
(Collated from the original results of Holme et al169). 
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fi lls the cytoplasm of unstimulated platelets. Actin fi laments connect with a 
submembranous latticework of short cross-linked actin fi laments, known as the 
membrane skeleton. One function of the cytoskeleton is to direct the contours 
of the membrane in the unstimulated platelet and the rapid changes in shape in 
the activated platelet. Activation-induced changes result from phosphorylation or 
calpain-induced cleavage of cytoskeletal proteins. The specifi c reorganizations 
depend upon the combination of signals to which platelets are exposed175. 
Platelet shape change follows a reproducible temporal sequence. When the 
platelet makes contact with a surface, the discoid shape is lost, and it becomes 
rounded or spheroid in form. Next, fi nger like projections grow from the cell 
periphery, then the platelet fl attens over surfaces and broad lamellae are extended. 
Granules and organelles are squeezed into the center of the cell, resulting in a fried 
egg appearance. Finally, a dynamic phase of membrane motility begins at various 
points along the lamellae, membrane ruffl es form and are retracted inward. Blunt 
fi lopods extend from the cell center and are rotated around the cell periphery. 
Exocytosis of granules occurs primarily into the OCS176. 
The protein activated by calcium to remodel the cytoskeleton is gelsolin, which 
is an abundant platelet protein (20 000 copies per platelet)177. Cellular gelsolin 
has been identifi ed as the main actin modulating protein178,179. Gelsolin has two 
actin binding sites and multiple calcium binding domains. Calcium binding opens 
the gelsolin molecule, allowing actin access to the actin binding sites of gelsolin. 
Actin binding activates the second site, causing gelsolin to interchelate into the 
fi lament, mediating the severing process. Platelets from gelsolin knock-out mice 
that lack gelsolin fail to undergo the normal shape change reaction. The interaction 
of gelsolin with actin is partially reversible. Amino acid change in gelsolin may lead 
to it’s abnormal fragmentation180.
Platelet shape change can be measured by an aggregometer. Transmission 
of the light decreases when platelets transform from discoid to a more spherical 
shape. The longer the formation of fi lopods lasts, the longer is the duration of 
shape change. Little attention has been paid to platelet shape change in patient 
samples in association with platelet aggregation studies181.
Extent of shape change and hypotonic shock response 
The ESC assay measures the proportion of platelets with a discoid morphology 
in platelets for transfusion. In the test, with the addition of EDTA (to prevent 
aggregation) and ADP (to activate the platelets), discoid platelets will undergo a 
rapid change to spherical forms. This transformation is associated with a decrease 
in transmitted light. The extent of decrease in transmitted light has been shown to 
be directly related to the percentage of discoid platelets in the platelet-rich plasma 
(PRP)182.
The HSR measures the ability of platelets to recover their volume after being 
exposed to a hypotonic environment. In the test, the addition of water to the 
cuvette containing PRP causes the platelets to swell because of the infl ux of water183. 
Platelet swelling results in a decrease in the refractive index of the platelets and an 
increase in transmitted light167. With maintenance of normal membrane integrity 
and energy metabolism, platelets are able to extrude the water to regain normal 
volume. 
As ESC and HSR reportedly correlate with the in vivo recovery percentage 
of radio-labeled stored platelets (R=0.71 and 0.57, respectively), the assays 
are considered the ‘gold standards’ for in vitro assays of platelet quality89,182,184. 
Although multi-laboratory comparative studies involving ESC have been relatively 
successful182,185, lack of stable controls has precluded further standardization of 
these biologic assays even within a single laboratory. Therefore, the use of more 
quantitative methods would be of value.
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Platelet aggregation in platelet rich plasma 
Platelet aggregation studies can be performed using PRP, washed platelets, or 
whole blood. Usually, platelet function is activated by primary agonists such as 
ADP, thrombin, and collagen, which react with their corresponding receptors 
on platelets. Secondary agonists like adrenalin do not induce aggregation on 
their own but become highly effective in the presence of low levels of primary 
agonists186. An antibiotic agonist, ristocetin, has been applied to measure vWF 
induced aggregation of platelets. 
Platelet aggregation under fl ow is a multistep process which involves exposure 
of vWf on the surface of platelets, platelet aggregation mediated by the binding of 
GPIbα on the surface of platelets to vWf, and an irreversible phase of aggregation 
dependent on GPIIb-IIIa64. 
Analyzing platelet aggregation responses in PRP is the most common method. 
Unaggregated platelets suspended in plasma create a turbid solution that absorbs 
light. An agonist to activate the platelets and induce aggregation is added to the 
PRP. The aggregated platelets fall to the bottom of the cuvette despite continuous 
stirring. This results in an increase in light transmittance through the sample. 
The platelet aggregation test is applicable to reveal major defects of receptors 
in inhibiting aggregation by a given agonist. Defective aggregation may also be 
due to disturbances in signal transduction mechanisms, as in acquired platelet 
function defects due to medication.
5.5 Platelet defects in Bernard-Soulier syndrome and Finnish type 
amyloidosis
Platelet disorders can be congenital or acquired. Congenital disorders (Table 3) 
have a lower incidence than acquired disorders. Congenital defects in platelet 
function are associated with bleeding manifestations of variable intensity and arise 
by diverse mechanisms. Defects of adhesion may arise because of qualitative or 
quantitative abnormalities in platelet GPIb or IX, the binding site on platelets for 
vWF. Disorders characterized by abnormal platelet-platelet interaction (disorders of 
aggregation) arise because of qualitative or quantitative abnormalities in platelet 
GPIIb-IIIa complex. Patients with abnormalities in platelet secretion and signal 
transduction are a heterogeneous group characterized by impaired aggregation 
responses and secretion of granule contents. A small proportion of these patients 
have defi ciency of granule stores (storage pool defi ciency) or impaired production 
of thromboxane A2; in most cases, the mechanisms underlying the platelet 
dysfunction are unknown.
Table 3. Congenital disorders in platelet function. (Modifi ed from Rao187.) 
Syndrome Disorder Cause for disorder
Bernard-Soulier syndrome Adhesion Deficiency or defect of GP Ib
Glanzmann's thrombasthenia Aggregation Deficiency or defect of GP IIbIIIa
Storage pool deficiency Secretion Abnormality of alfa-granules
Gray platelet syndrome Secretion Deficiency of GPVI* or alfa-granules
Wiscott-Aldrich syndome Secretion Defects in cytosceletal regulation
Defects in ADP-aggregation Secretion Defects in P2 receptors**
*188 **26
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Bernard-Soulier syndrome 
More than 50 years ago Bernard and Soulier described a congenital bleeding 
disorder in patients who had unusually large platelets, a moderate degree of TP, 
and a markedly prolonged bleeding time14,15.
BSS is an example of macro TP and a defi ciency or defect of the major adhesion 
receptor of platelets, the GPIb-IX-V complex.  In classical BSS, the whole protein 
complex is absent, but in variant BSS, the expression of complex is reduced31. 
Most of the mutations associated with BSS locate in the GPIbα gene and lead 
to either total or reduced expression of GPIb, GPIX, and GPV on the cell surface. 
Although mutation of the gene encoding GPIbα is most common in BSS, defective 
GPIbβ or GPIX expression has also been observed189-191. The mutations in the GPIX 
gene or in the promoter region of the GPIbβ gene may lead to reduced expression 
of GPIb, GPIX and GPV15.  It is not known why a defect in the vWF receptor causes 
macro TP and what is the role of the vWF receptor in thrombopoiesis. Because 
the platelets in BSS are often extremely large (approximately 15-30 fl ), the size 
may infl uence their detection in cell counters. When PRP is used in analyses, large 
platelets can be lost by centrifugation.
The differential diagnosis of BSS from treatment-resistant ITP is diffi cult. The 
defect is measured from the platelet membrane by fl ow cytometry, thus confi rming 
the diagnosis, or by a defi cient response to ristocetin in the platelet aggregation 
test. 
Finnish type amyloidosis(FAF) 
Hereditary gelsolin-related amyloidosis (AGel amyloidosis) is a systemic disorder 
caused by a G654A or G654T mutation in the gene coding for gelsolin, an actin-
modulating protein192-194. The principal clinical manifestations are corneal lattice 
dystrophy, cranial and peripheral neuropathy, and cutis laxa193. The gene defect of 
FAF results in deposition of amyloidal fi brils at extra-cellular sites in most tissues, 
including the central nervous system195,196.
Gelsolin-defi cient platelets in knock-out mice have been reported to respond 
weakly to all agonists, to spread poorly, and to have reduced capacity to nucleate 
and assemble actin fi laments197. The infl uence of FAF mutation on human platelet 
function is not known. 
5.6 Platelet antibodies 
Platelet alloantibodies
The internationally organized platelet alloantigenes belong to biallelic human 
platelet alloantigen systems (HPA)198. NAIT may arise if the mother is homozygous 
for a particular allele and develops alloantibodies to an alternative allele. It has 
been observed that although approximately 1% of mothers develop alloantibodies, 
only 0.1% of neonates suffer from NAIT.
Anti-HPA-1a is the most common cause of NAIT (80%) in Caucasians199. 
Anti-HPA-5b is the second most common cause (3.8-4.3%)200. Anti-HPA-5b is 
thought to be milder and have fewer complications than NAIT caused by anti-
HPA-1a because of the lower number of HPA-5b antigenic sites per platelet200,201. 
Two new alloantigens have been recognized fi rst in the Finnish population (Va 
and Tu=6b)202,203. Recently the HPA-15 system has been revealed as a relatively 
common cause of platelet alloimmunization204.
Platelet autoantibodies 
Both platelet destruction and suppression of platelet production seem likely to be 
involved in the pathogenesis of ITP which is still considered as a heterogeneous 
disease17. 
22
The presence of antiplatelet factors in ITP was shown already in 1951 when 
plasma from an ITP patient induced TP in a normal recipient13. Patients with 
chronic ITP often have GP-specifi c antibodies205. Most PA-IgG is against GPIIb-IIIa 
or GPIb-IX. GP-specifi c antibodies have been suggested to have a defi nite role in 
the diagnosis of ITP206.
Platelet production is not increased in all ITP patients, and their turnover is 
decreased or normal in two-thirds of patients207. This may be due to an antibody 
effect on megakaryocytes, because they are known to express GPIIb-IIIa and GPIX 
on their surface56,208. The binding of autoantibodies to megakaryocytes may initiate 
cell death, because in morphologic studies of adult ITP patients the majority of 
megakaryocytes were abnormal209.
Autoantibody-coated platelets are phagocytized in the reticuloendothelial 
system via Fcγ receptors on mononuclear macrophages. Recent evidence suggests 
that platelets are also destroyed by cytotoxic T cells210.
When the epidemiology of ITP was studied to defi ne clinical subgroups and to 
investigate factors predicting chronic disease, chronic ITP developed in 25% of the 
affected children. In childhood ITP patients, autoantibodies against either GPIIb-
IIIa or GPIX were suggested to be the cause of platelet destruction and they were 
also shown to inhibit megakaryocytopoiesis when patient plasma was incubated 
with cord blood mononuclear cells in the presence of TPO56. 
Platelet-associated IgG (PA-IgG). The American and British guidelines conclude 
that current tests, including PA-IgG measurement, for platelet antibodies are 
neither necessary nor appropriate in the evaluation of ITP211,212.
The measurement of PA-IgG is sensitive but not specifi c enough for the diagnosis 
of ITP. GP-specifi city of PA-IgG is considered a more specifi c method213. 
Glycoprotein specifi city of PA-IgG. GP-specifi city can be measured by several 
immunological methods that differ from each other in specifi city and sensitivity 
(Table 4).
In chronic ITP, antibodies reactive with GPIIb-IIIa or, more rarely, GPIb-IX are 
most prevalent56,218,219. Autoantibodies to platelet GPIIb-IIIa measured from sera 
by immunobead assay were detected in children with chronic ITP but not in children 
with acute ITP (n=24 and 15; GP-specifi city in 58% and 27%, respectively)220. 
Brighton et al used GP-specifi city for distinguishing immune from nonimmune 
TP213.
Technique GP N Sensitivity 
%
Specificity 
%
Reference 
Maipa IIb-IIIa and IbIX 158 51 85 213 
MACE* IIb-IIIa, IbIX, and IaIIa 104 60 97 214
Immunobead IIb-IIIa or IbIX 571 66 93 215
PakAuto** IIb-IIIa, IbIX, and IaIIa 46 53 72 216
Flow cytometry IIb-IIIa and Ib 76 86 100 71
      
SASPA*** IIb-IIIa, IbIX, IaIIa, IV, 
CD109 
29 n.s. n.s. 217 
*Modified antigen-capture enzyme-linked immunosorbent assay 
**Solid Phase enzyme-immunoassay, commercial 
***Simultaneous analysis of specific platelet antibodies  
Table 4. Sensitivity and specifi city of the GP-specifi c PA-IgG assay. 
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GPV-specifi c PA-IgG may represent an important target antigen in autoimmune-
mediated TP, especially when drug-induced. Altogether, 16 of 366 patients had 
GPV-specifi c autoantibodies, while four of them could be associated with quinidine 
and gold-ITP57.
Patients with autoantibodies directed towards both GPIIb-IIIa and GPIb-IX 
receptors may have a severe bleeding tendency219.
The assay of antigen-specifi c autoantibodies may be a useful prognostic tool for 
predicting the clinical course of ITP patients. The presence of immune TP is highly 
probable (>90%) if the antigen-specifi c assay is positive. Although the positive 
assay has been considered diagnostic, a negative assay does not rule out the 
diagnosis72.   
5.7 Platelet products for clinical transfusion 
Most platelet research has been done using PCs prepared by the s.c. PRP 
methods. PCs can be prepared by single centrifugation of fresh whole blood to 
PRP from buffy-coat of 4-6 fresh whole blood units and by apheresis221. Strict 
guidelines govern the preparation of units: centrifugation forces, separation 
techniques, platelet concentration, and storage temperatures must be optimized 
and other recommendations and quality requirements followed142.                           . 
5.8 Quality assurance in platelet analytics
The performance of analytical methods in quantitative clinical chemistry can 
be monitored by analyzing specimens whose concentrations are known, and 
by comparing the observed with the known values (control limits)225. When the 
observed control values, presented in Levey-Jennings charts226, fall within the 
limits of the Westgard rules227, the analyst can be assured that the analytical 
method is working properly. When the observed values fall outside Westgard 
rules, the analyst should be alerted to the possibility of problems in the analytical 
process. Although the application of Westgard rules has become a requirement in 
quantitative tests, quality monitoring in qualitative tests is in its infancy228. Patient 
means may also be used to monitor the stability of measurements229,230.
One of the aims of the present study was to show whether in accredited 
It must be kept in mind that in most of the published studies PRP platelets 
have been used, and therefore the results may differ from each other.
Methods for detecting the activation state (ESC, HSR, CD62P, CD63, GPV) 
of platelets in PCs have been laborious and the reproducibly of methods is 
not always good90,185,223,224. The in vitro assays commonly used to assess 
platelet quality in addition to platelet count and swirling are metabolic tests, 
such as pH, pO2, pCO2, rate of lactate production, and oxygen consumption 
rate224. The detection of activation of platelets is not in routine use
 It was known already in the 1970s that optimal techniques are needed for storing 
PC for transfusion. For example, gentle agitation is needed, extreme changes in 
pH must be prevented, and the container material must enable gas exchange222. 
Despite continued efforts to improve the process and major advances in establishing 
optimized storage conditions, platelet storage lesion still occurs. This is characterized 
by loss of function and changes in morphology associated with platelet activation 
and vacuolization, microvesiculation and fragmentation. Poor quality of platelets 
may lead to a decrease in post transfusion recovery and shortened survival time of 
platelets in circulation. Low or high pH (<6.4 or >7.4, respectively) of the platelet 
storage medium is associated with poor platelet recovery and survival. No single 
laboratory test refl ects the eventual hemostatic function of platelets in vivo139. 
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surroundings it is possible to apply the quality control rules of quantitative analysis 
also to qualitative, validated analyses. It is important to aim at improving quality 
continuously. 
5.9 Laboratory instrumentation
Cell counters
Although many cell counters include fl ow cytometric principles in white cell 
counting, platelet count and volume can be measured by other techniques, 
such as impedance, hydrodynamic focusing, and optical methods231,232. Most 
hematology analyzers use the impedance principle, the differences between 
instruments depending on different algorithms for calculating the results. The 
electric impedance method can estimate the volume of each cell exactly. However, 
diffi culties can emerge in discriminating large platelets and small red cells. In such 
cases, discrimination can be done with a light scattering method. The use of fl ow 
cytometric technology for detection of platelets is increasing. 
For detection of platelet count, the impedance method is commonly used. MPV 
can be calculated from the equation but its use is limited because of small platelet 
mass:
In optical methods, MPV is measured from the scattering properties of platelets.
  
Impedance method. The diluted sample is pressed through an aperture equipped 
with a platinum electrode on both sides. An electrical current is applied between 
the electrodes. When a cell is drawn through the orifi ce, the electrical conductivity 
changes, and an equivalent voltage pulse is generated. The number of pulses 
corresponds to the number of cells detected. The total number of platelets is the 
value shown on the display screen multiplied by the dilution factor. The amplitude 
of the pulse is directly proportional to the volume of the represented cell, and MPV 
is determined from the platelet size distribution curve as a mean value. 
Hydrodynamic focusing with impedance detection. Inside the detector, the sample 
nozzle is positioned in front of the aperture and in line with the center. After the 
diluted sample is forced from the sample nozzle into the conical chamber, it is 
surrounded by front sheath reagent and passed through the aperture center. After 
passing the aperture, the diluted sample is sent to the catcher tube. This prevents 
the blood cells in this area from drifting back, avoiding the generation of false 
platelet pulses. However, the impedance method is used for detection of platelets 
also in this type of instrument. 
Impedance method and an ‘optical’ platelet count using a fl uorescence dye.  The 
new diagnostic options allow the measurement of total platelet count and RP 
simultaneously. With this method IPF can be measured by staining the RNA of RPs 
with polymethine-oxazine dye151,152. The use of the ‘optical’ platelet count has been 
shown signifi cantly improve the reliability of low platelet counts233. 
The introduction of fl uorescent fl ow cytometric analysis allows extended 
quantifi cation of additional cell populations233.
 
Although hematology analyzers may provide reliable full blood counts from blood 
samples of healthy volunteers234, they are known to give variable results when 
Plateletcrit (%)
Platelet count (x10
6
/ml)
MPV (fl) = x 1000
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enumerating platelets in severe TP. If the thresholds for platelet transfusion, 
currently set at 10 x 109/l, are to be further reduced, it is vital that the limitations 
of current analyzers are fully understood232. In a large multicentre study of the 
accuracy of hematology analyzers there was variation in platelet counts between 
different analyzers and even with the same type of analyzer at different sites. 
  
Flow cytometry 
Since the 1960s, fl ow cytometers have rapidly evolved into today’s versatile 
instruments235-237. 
Principle of fl ow cytometry. Flow cytometry measures the specifi c characteristics 
of numbers of individual cells in suspension. Single cells in suspension are 
fl uorescently labeled, typically with fl uorescently conjugated monoclonal antibody. 
Current cytometers may be equipped with more than one laser as light source, 
which enables the use of one or more fl uorescent colors.  The most commonly 
used dyes are fl uorescein-isothiocyanate (FITC), which emits light at 530 nm 
wavelength, and phycoerythrin (PE) which emits light at 575 nm. During the 
analyses, air pressure is used to push suspended cells in a sheath fl uid through 
the fl ow chamber, and the focused beam of a laser (usually Argon laser). The 
rate may be adjusted from 100 to 100 000 cells per minute. After the laser light 
activates the fl uorophore(s) at the excitation wavelength(s), detectors process the 
emitted fl uorescence and light-scattering properties (forward scatter light, FSC 
and side scatter light, SSC) of each particle. The current from each photo detector 
is converted into a voltage, which is then amplifi ed, and fi nally digitized by an 
analog-to-digital converter into values in digital channels. The amplifi cation can be 
linear or logarithmic. The intensity of the emitted light is directly proportional to 
the antigen density or the characteristics of the cell being measured238. Mean FSC 
measures the size of the particle (cell) and SSC its complexicity (granularity).
Use of fl ow cytometry in platelet analytics. Flow cytometric techniques have 
also proved useful in platelet studies during the past 20 years. Before then, the 
small particles found in blood were often referred to as “debris”. The biological 
and physical properties of platelets necessitate different methods of preparation, 
labeling, and analysis than for other cell types239.
There are many advantages of fl ow cytometric analysis of platelets. In whole 
blood, platelets are directly analyzed in their physiological milieu. The minimal 
manipulation of the samples prevents activation and potential loss of platelet 
subpopulations. Thus the activation state of circulating platelets can be determined. 
Several monoclonal antibodies can easily be incorporated into the assay. Another 
advantage is that knowledge about platelets can be derived on the basis of their 
FSC and SSC properties.
There are also some disadvantages of fl ow cytometric analysis. Flow cytometers 
are expensive instruments to purchase and maintain. Moreover, sample preparation 
can be quite complicated, although the development of commercial kits has 
simplifi ed some of the assays. 
To avoid ex vivo platelet activation, it has been suggested that for some assays 
blood samples should be processed within approximately 30 minutes of drawing, 
or if this is not possible, the cells should be fi xed. 
Flow cytometry was used in the present study to measure platelet activation, 
diagnose specifi c disorders (BSS), monitore thrombopoiesis (RPs), measure of PA-
IgG, and to measure platelet size240,241. 
Aggregometry
The need for quantitative yet robust assessment of platelet function led O’Brien 
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and Born to independently develop platelet aggregometry in 1962242,243. In the 
simple turbidometric method platelet poor plasma is set at the 100% platelet 
aggregation level and PRP at 0% platelet aggregation level. Sample requirements 
are demanding. The patient sample should be taken after at least a three-hour 
fast. Lipemic samples and patient medication may cause decreased aggregation 
responses. Analysis should be performed within two hours after the blood sample 
was drawn. The sample must be handled with care to exclude any platelet activation 
during processing.
 When aggregates are formed after the addition of an aggregating agent (e.g. 
ADP, adrenaline, collagen, ristocetin), there is an increase in light transmission and 
wider defl ections in the recording. Different agonists produce different patterns of 
aggregation. ADP, for example, produces a double wave of platelet aggregation 
at low doses; the second wave depends on the induction of the release reaction, 
wherein platelets release the contents of their granules, including the platelet’s 
own storage pool of ADP. From aggregation curves, the maximum aggregation and 
velocity are measured (Figure 5, Chapter 7.2.5). It is also possible to measure the 
area under the aggregation curve, which necessitates use of specifi c software. 
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6 AIMS OF THE STUDY
In this study was investigated the association between platelet analytical methods 
and diseases linked to TP, and changes during platelet concentrate storage. In 
addition, traditional and novel analytical methods were compared.
(1) It was hypothesized that the G654A mutation of gelsolin would produce 
changes in human platelet function, because lack of gelsolin in transgenic mice 
causes decreased platelet shape change and prolonged bleeding. Platelet function 
was studied in FAF patients, their healthy siblings, and healthy volunteers using 
platelet shape change and aggregation measurements applying several agonists.
(2) There was a unique opportunity to test platelet GPIb-IX-V expression in 
several BSS families with the same GPIX mutation, including follow-up of one 
propositus for several years. 
(3) It was not known if TPO is present in amniotic fl uid and in fetal plasma and 
if their concentrations would correlate with each other or with fetal platelet count. 
The kinetics of endogenous TPO was studied in cord blood plasma and amniotic 
fl uid during pregnancy of mothers with confi rmed or probable fetal alloimmune 
TP. 
(4) As there was evidence that patients with autoimmune TP have platelets 
which are larger than those of healthy individuals, quantifi cation of platelet size 
by fl ow cytometry was performed from the same sample in which the platelet 
antibodies were measured. The presence of PA-IgG was also related to the 
presence GP-specifi c antibodies. 
(5) There is a need for non-invasive methods to characterize pathogenesis of 
TP in chronic TP of childhood. It was hypothesized that an array of methods (PA-
IgG, platelet count, MPV, RP, TPO, membrane GPIb-IX) would predict the clinical 
course of the disease. Samples from children with chronic ITP were analyzed 
prospectively.  
(6) There is a need for a repeatable and inexpensive measurement of platelet 
quality in platelet storage media to circumvent the need for more laborious, poorly 
repeatable tests of platelet function and surface markers. The suitability of a 
new platelet marker, soluble GPV, for the measurement of the quality of PCs was 
evaluated by comparing its performance to other selected methods. 
The precision and stability of the methods were in the main focus of the study. 
Demanding criteria were used when choosing the methods, and the results were 
subjected to critical interpretation. 
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7 MATERIALS AND METHODS
7.1 Materials 
7.1.1 Ethical aspects
The prospective studies were approved by the hospital’s ethics committee 
(III), written informed consent being obtained in each case (III). Informed oral 
consents were obtained from all study subjects in the case series (I, II, V). In 
the retrospective studies (II, IV), new methods of data analysis were developed. 
The analyses were performed and interpreted blinded. The study concerning PCs 
belonged to the approved product development scheme. 
7.1.2  Patient samples and their controls
The numbers of patient samples and controls used in different studies are 
summarized in Table 5A, Chapter 7.1.3. 
Study I. The prospective controlled study comprised 20 amyloidosis patients 
with a G654A gelsolin gene mutation (13 women, seven men, median age 54.4 
years, range 29-76), 10 healthy siblings without G654A mutation (three women, 
seven men, median age 40.6 years, range 35-60), and 20 healthy control subjects 
(17 women, three men, median age 38.5 years, range 25-54). Sodium citrated 
samples (1 ml 3.8% sodium citrate dehydrate and 9 ml blood) were collected, and 
the interpretation of results was performed blinded. Samples were analyzed pair-
wise, grouped as follows: seven patients and unrelated controls, 10 patients and 
healthy siblings, 13 patients and healthy controls. Five patients and two healthy 
siblings had taken medication.
Study II. Seven patients (fi ve propositi) from fi ve unrelated families with BSS 
were investigated in the case series. Samples were also obtained from parents 
and two siblings from one family, and from one sibling and one child from two 
other families. Three propands and one sibling had been treated earlier with 
corticosteroids and two propands had been splenectomized. BSS diagnosis was 
confi rmed by gene mutation analysis in addition to defi cient platelet aggregation.
Study III. Cord plasma and amniotic fl uid were collected from 15 consecutive 
fetuses at risk of NAIT in the prospective case series. Serial samples from fi ve 
fetuses with severe TP due to HPA-1a alloimmunization were collected at 22 to 28 
weeks of gestation during investigations for clinical reasons. Samples were also 
collected from 10 healthy term infants delivered by elective caesarean section, and 
from 14 healthy controls.
Study IV. The retrospective study comprised reanalysis of primary results 
obtained in routine analytics of samples from 854 thrombocytopenic patients with 
suspected autoimmune TP. The samples were sent to the platelet laboratory from 
hospitals throughout the country within one year (2003). Indications for platelet 
antibody testing as well as the lowest platelet count (historical platelet nadir) were 
requested in the referrals of the samples. Venous blood was collected in three 10 
ml vacuumed EDTA tubes (Venoject® 288267, Terumo, Leuven, BE or Vacutainer® 
368457, Becton Dickinson, NJ, US), which were transported at room temperature. 
The samples were handled within 24 hours. Altogether, 112 healthy controls were 
analyzed together with patient samples during the year. 
Study V. Twenty-one, consecutive pediatric patients, who had an isolated 
chronic TP (median 4.3 years, range 0-14.3) attending any of the three hospitals 
was investigated in the prospective controlled study. Two of them had been 
splenectomized. Samples from six healthy children (median 13.2 years, range 6.8-
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14.9) served as controls. A freshly drawn sample from a healthy volunteer adult 
was analyzed as a control (n=14).
Study VI. The study comprised altogether 96 platelet units. Two leukocyte poor 
buffy coat -derived PCs (four units each) were pooled and each pool was further 
realiquoted to obtain homogenous four unit paired products for the study material 
(n=24). One product was stressed by transportation and the other half of each pair 
was stored with controlled agitation. 
Whole blood units were initially stored at room temperature (+22°C) for 16-22 
hours and then centrifuged for 13 min at 5135 g. Blood components (plasma, buffy 
coat and red blood cells) were separated using an automatic separator (Optipress 
II, Baxter Healthcare Corporation, Fenwal Division, Deerfi eld, IL, US). After two 
hours resting time, four buffy coats (BCs) of about 47 ml of volume and with a 
hematocrit of 0.50 were pooled together using a sterile connection device (TSCD, 
Terumo, JP)244. The BCs of four blood units were combined in one bag by fl ushing 
all BC bags with one unit (300 ml) of platelet additive solution (T-Sol, Baxter, 
Lessines, BE). After a second centrifugation for three min at 1283 g to remove 
other contaminating blood cells, the platelet rich supernatant was passed through 
a leukoreduction fi lter (ATSBC, Pall Medical, Covina, CDN). Pooled, leukocyte 
reduced platelet concentrates (leucocyte contamination <1 x 106/unit) were stored 
in a 1000 ml storage container (UPX-80, JMS, Hiroshima, JP). At the time of the 
study, the fi nal concentration of plasma in the storage medium was approximately 
20%. 
Twelve platelet products were stored for six days with controlled agitation at 
22°C. The other 12 products were shipped overnight to a regional blood bank 
on day 1 (n=6) or 3 (n=6), where they were stored and returned on day 5 or 4. 
The samples were taken from six products on day 1 and 3 before transportation 
(n=12), and from all products on day 6 (n=24) (Figure 3).
Table 5. Number of patient samples and their controls used in studies (A). Number 
of controls used for measurement of reference values and repeatability of the 
assays (B).
A Method
Samples Patients Controls Other 
controls
Publication
Shape change,aggregation 20 20 10 sibs I
GPIb-IX-V expression, aggregation 12 7 11 5 II
TPO 23 15 14 12 newborn III
PA-IgG (MFI), FSC 854 112 IV
GPIIb-IIIa/Ib-IX-specificity of PA-IgG 206 63
PLT count, MPV, RP, TPO, GPIb-IX, GPIIb-IIIa 21 14 6 children V
PA-IgG (MFI) 12 12 5 children
PLT count, MPV, CD62P, CD63, ESC, HSR 36 6 VI
soluble GPV, pH, CO2, O2, Lactate, Glucose
Reference/cut-off 
values
Shape change 20
Aggregation 20
GPIb-IX-V expression 114
TPO -
PA-IgG (MFI), FSC 112
GPIIb-IIIa/Ib-IX-specificity of PA-IgG -
PLT count, MPV -
RP 14
CD62P, CD63, ESC, HSR, soluble GPV -
pH, CO2, O2, Lactate, Glucose -
Intra-assay 
repeatability
Inter-assay       
repeatability
6
6
6
-
6
-
-
10
14
6
2
10-
Samples (n) 
B
8
-
-
-
5
112
50
30
7.1.3 Reference samples
Healthy controls were used for determining the reference values whenever it 
was possible (Table 5B). It was not the purpose of the study to set any reference 
range for TPO, ESC, HSR, CD62P, or CD63 measurements, but to compare results 
between groups or longitudial samples.
7.2 Methods
The different methods used in studies I-VI are presented in Table 5A. All of them 
are described separately in the following sections.
7.2.1 Platelet count and size measured by cell counters (I-VI) 
Platelet count and MPV were determined with an electric cell counter (Medonic, 
Solna, Sweden). Before counting the blood sample was diluted 1:40000 (FACS 
Flow, Becton Dickinson, San Jose, CA, US). The dilution was performed manually 
in two steps (fi rst 1/400, second 1/100) in order to spare the samples of 
thrombocytopenic patients. The controls were commercial (Sysmex e-Check, 
Sysmex Corporation, Kobe, JP, and B-Trol Plus I, Bioclin, Helsinki, FI).
An impedance detection method (Medonic) was compared with the hydrodynamic 
focusing detection method (XT-2000i; Sysmex Corporation, Kobe, JP) (n=52), 
where the sample dilution of 1:500 was made automatically. 
7.2.2 Platelet size measured by fl ow cytometry (FSC) (II, IV)
Platelet size was measured by fl ow cytometry in association with PA-IgG or 
membrane GP-measurements (see 7.2.11 and 7.2.12). For the fi rst assay (PA-
IgG), samples were drawn one day and for the second assay (membrane GP) 
maximally six hours before the measurement. Size was presented as the median 
of the forward scatter distribution (FSC) of all platelets at linear scale. 
Controls were the same as in the membrane GP and PA-IgG -measurements. 
(7.2.10 and 7.2.11).
Depending on the context, platelet size measurements as either MPV or FSC 
are used synonymously.
Platelet
product
(n=6)
transported Day 1 and Day 3
non-transported
Day 1
Platelet
product
(n=6)
transported Day 3 
and Day 4 
non-transported
Day 3 Day 6
Platelet
product
(n=6)
Platelet
product
(n=6)
Figure 3. Schematic presentation 
of sampling of platelet products 
during transportation or normal 
storage.
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7.2.3  Reticulated platelets (RP) (V)
The citrated samples were shipped to the laboratory by the hospital within one hour 
of sampling. The assay was performed as described by us in detail245. Platelets in 
PRP (500x109/l) were fi xed with paraformaldehyde. 10 µl of platelets was incubated 
with 90 µl of thiazole orange reagent, which permeates cell membrane and binds 
to intracellular nucleic acids (RetiCount, Becton Dickinson, San Jose, CA, US) for 
60 min at room temperature in the dark. Samples were diluted with 400 µl of fl uid 
(FACS Flow, Becton Dickinson, San Jose, CA, US) and the analyses were run on the 
fl ow cytometer (FacsScan, Becton Dickinson, San Jose, CA, US). After acquisition 
of 50 000 events the FSC/TO scattergram (CellQuestTM, Becton Dickinson, San 
Jose, CA, US) was used to set for gating. A freshly drawn sample from a single 
healthy control was used in every measurement.  For the control sample, in the 
FSC vs. fl uorescence plot, a slope line segregating 95% of the events below the 
line was set parallel to the platelet cluster leaving the RPs above the line. Patient 
samples were analyzed using the line of the control sample as the discriminator. 
RP was expressed as the percentage of total platelet number.
7.2.4  Thrombopoietin (TPO) (III, V)
Cord blood samples for plasma separation, taken into citrate tubes, and amniotic 
fl uid samples were kept chilled. The contaminating cells were removed by 
centrifugation at 1000xg and at 10 000xg at 2-8°C. The centrifuged samples 
were stored at -20°C. The samples were taken during diagnostic umbilical vein 
punctures before eventual platelet transfusions. 
In thrombocytopenic children, the citrated samples were taken during routine 
visits to the hospital. These samples were shipped to the laboratory within one 
hour of sampling.
TPO was measured in duplicate using a commercial human TPO ELISA kit 
(QuantikineR, R&D Systems, Abingdon, UK). 200 µl of platelet free plasma/
standard was incubated for three hours refrigerated in a micro plate precoated 
with monoclonal antibody for TPO. Any TPO present was bound by the immobilized 
antibody. After washing away any unbound substances, 200 µl of an enzyme-linked 
monoclonal antibody specifi c for TPO was added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, 200 µl of substrate solution was 
added to the wells. The color developed was in proportion to the amount of TPO 
bound. The intensity of the color was measured after 30 min incubation at 450 nm 
(Multiscan EX, Thermo Electron Corporation, Vantaa, FI). The TPO concentration 
of the sample was calculated from the standard curve. The two-level controls were 
of the kit.
The lower limit of detection according to the manufacturer was 25 pg/ml. In 
the present study, the method was linear up to 7 pg/ml (Figure 4).
R = 0.999
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Figure 4. Linearity of the TPO 
measurement (absorbance of blank was 
not deducted) (range 0-200 pg/ml).
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7.2.5 Platelet shape change and aggregation in PRP (I, II)
After an initial platelet count from citrated sample (Medonic), PRP was prepared 
by centrifugation (350xg, 10 min). Autologous platelet poor plasma (<20x109 
platelets/l) was prepared by centrifugation of plasma (1600xg, 15 min) and used 
for dilution to obtain a suspension of 200-300x109 platelets/l for analysis. If the 
concentration could not be achieved due to TP, the low concentration was taken 
into consideration when interpreting the results. The total time from drawing the 
blood sample to the end of the registrations did not exceed three hours. 
Platelet shape change and aggregation were monitored by registering changes 
in the optical density of PRP in an aggregometer (PACKS-4, Helena Laboratories, 
TX, US), according to the method of Ludlam246. 
First, the four channels of the aggregometer were adjusted to 100% light 
transmission with platelet poor plasma. After that, 450 µl of PRP was pipetted 
into a cuvette containing a magnetic stirrer (stirring rate 1000 rpm/min), and 
warmed up to 37°C for three minutes. Platelet aggregation was induced by adding 
to PRP 50 µL of agonists: adenosine diphosphate (1, 3, and 6 µg/ml, at fi nal 
concentrations; Roche Diagnostics, Mannheim, DE), arachidonic acid (1.2 mmol/l, 
at fi nal concentrations; Nu Check Prep Inc, Elysian, MI, US), adrenaline (0.9, 9, 
and 54 µg/ml, at fi nal concentrations; Leiras, Helsinki, FI), ristocetin (0.75, 1.25, 
and 1.50 mg/ml, at fi nal concentrations; American Biochemical & Pharmaceutical 
Corporation, NJ, US), and collagen (0.42 and 0.84 µg/ml, at fi nal concentrations; 
Nycomed Arzneimittel, Linz, AT). The aggregation reaction was followed for eight 
minutes. To defi ne platelet aggregation the percentage of the maximal aggregation 
(A, %) and the maximal aggregation velocity (Av, %/min) were measured (Figure 
5). For the biphasic adrenaline-induced stimulation two velocities were obtained. 
Decrease of optical density was measured as a new method to characterize 
platelet shape change. Decrease of optical density was expressed as a percentage 
(D) and the duration of shape change in seconds (T) (Figure 5). The shape change 
was registered for ADP, arachidonate, and collagen as agonists. 
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Figure 5. Shape change, maximal 
aggregation A (%), and maximal 
aggregation velocity Av (%/min) after 
collagen induction (0.42 µg/ml). T is 
duration of the shape change (s) and 
D is the maximal decrease in light 
transmission during shape change 
(%).
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7.2.6 Platelet swirling (VI)
Swirling of platelets was scored by the naked eye. A score of one means very poor 
swirling with simultaneous aggregates. A score of four means clear “hairs” during 
the whole storage period indicating the gradual change of discoid platelets into 
spheres. In the normal quality assurance of PCs swirling was categorized either 
by the presence of “hairs” formed by moving discoid platelets or by the loss of 
them.
7.2.7 Extent of shape change and hypotonic shock response (VI)
The ESC measurement was performed according to Holme et al with slight 
modifi cations 182. Due to the use of pooled PCs, the dilution matrix was blood 
group AB plasma instead of autologous platelet poor plasma, which can be 
used if platelets are from single donors. EDTA was added to the sample to bind 
calcium more effi ciently than citrate in order to prevent aggregation after agonist 
stimulation. Calculation of results was simpler because of different aggregometer 
output.
In the test, discoid platelets will undergo a rapid transformation into spherical 
forms. Added EDTA prevents aggregation and ADP activates the platelets. The 
extent of decrease in transmitted light has been shown to be directly related to the 
percentage of discoid platelets in the sample182.’
The samples from platelet products were placed in CTAD tube (citrate solution, 
theophylline, adenosine and dipyridamole; VacuetteR, Greiner Bio-One GmbH, AT) 
and diluted with AB plasma to a platelet count of approximately 300 x 109/l.  The 
samples were incubated at 37°C for 30 min before measurement. The channels 
of the aggregometer were adjusted to 100% light transmission with AB plasma. 
After that, 400 µl of diluted PC sample was added into two cuvettes containing a 
magnetic stirrer (stirring rate 1000 rpm/min). 50 µl of warmed 20 mM EDTA was 
added into a sample cuvette. After 15 sec, 50 µL of warmed 0.2 mM ADP was 
pipetted into the sample cuvette. The reaction was followed until shape change 
was complete (at least 2 min). The percentage decrease of transmittance to ADP 
as an agonist was calculated. 
The same technician performed all measurements blinded and in duplicate. 
The samples were also kept blinded during the calculation of results.
The HSR measurement was performed according to Holme et al with slight 
modifi cations as in the ESC measurement182. HSR measures the ability of platelets 
to recover their volume after being exposed to a hypotonic environment. 
The samples from platelet products were handled similar to those for ESC. An 
aliquot of 300 µl of the samples was added to four cuvettes containing a magnetic 
stirrer (stirring rate 1000 rpm/min). 150 µl of warmed phosphate buffer (PBS; 
Na2HPO4 0.0090 mol/l, NaH2PO4 0.0013 mol/l, NaCl 0.1403 mol/l, pH 7.2) was 
added into two of the samples, and 150 µL of warmed water into the two other 
samples. The reaction was followed until the change in extinction was equilibrated 
(at least 5 min). 
HSR was calculated by the equation:
  %HSR= 100 * T4min/(Tmax-TPBS) T= light transmission
The same technician performed all measurements blinded and in duplicate. 
Also during the calculation of results, the samples were kept blinded.
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7.2.8 Soluble GPV (VI)
Samples for soluble GPV were stored frozen at –70°C. A commercial ELISA kit 
was used to quantify sGPV (Asserachrom® Diagnostica Stago, Asnieres, FR). The 
sample containing soluble GPV was added to a plastic micro well precoated with a 
monoclonal antibody to soluble GPV. Antigen was immobilized by one of its epitopes 
and revealed by the peroxidase coupled another monoclonal antibody, directed 
against another epitope of the soluble GPV. The level of bound peroxidase was 
measured by its action on the orto-phenylenediamine substrate in the presence 
of peroxide. After stopping the reaction with sulfuric acid the intensity of the 
color produced had a direct relationship to the soluble GPV concentration initially 
present in the plasma sample. The results were read from the log-log curve. All 
assays were performed in duplicates. The two-level controls were commercial (Low 
and high control, Asserachrom® Diagnostica Stago, Asnieres, FR).
The maximum activation of platelets was evaluated separately by thrombin 
activated platelets (Thrombin, T6884, Sigma chemical Co, MO, US; 1 IU of 
thrombin /ml of PRP with 500 x 109 platelets/l) as suggested elsewhere 103. 
   
7.2.9 Expression of CD62P and CD63 (VI)
The CD62P measurement was performed according to a recommendation of the 
BEST collaborative223. Immediately after collection of the PC sample (500 x 109 
platelets/l) or IgG control sample, 10 µl of the sample was stained with 10 µl of 
fl uorochrome-labeled monoclonal antibodies (FITC labeled anti-CD41; Biodesign, 
Kennebunk, ME, and phycoerythrin (PE) labeled anti-CD62P; CLB, NL). The 
samples were incubated for 15 min at +37 °C in the dark. Nonspecifi c binding was 
controlled by using mouse IgG1 (Simultest TM, Becton Dickinson, San Jose, CA, 
US). 
The maximum activation of platelets was evaluated by activating the whole 
blood with thrombin247. 
After incubation, samples were diluted to 1 ml with FACSFlow and analyzed by 
fl ow cytometry. The 500 000 events collected were acquired and analyzed using 
FITC/PE dot plot and quadrant analysis (Cell Quest program, Becton Dickinson, 
San Jose, CA, US). The lower left quadrant (Figure 6A) was set to include 99% of 
events from the control. At least 95% of events in the activated control sample 
were in the upper right quadrant (Figure 6B). The percentage of platelets observed 
in the upper right quadrant was defi ned as the percentage of cells expressing 
CD62P compared with the controls.
The same technician performed all measurements blinded in duplicate. The 
samples were also kept blinded during the calculation of results. 
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Figure 6. Quadrant analysis in CD62P analysis of non-specifi c binding (A) and 
thrombin activated PC (B). The proportion of CD62P-positive platelets in the upper 
right quadrant was 98.7%.
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The CD63 measurement was performed with the CD62P measurement but 
with different fl uorochrome-labeled monoclonal antibodies (PE labeled anti-CD41; 
Biodesign, ME, US, and FITC labeled anti-CD63; CLB, Amsterdam, NL). 
7.2.10 Expression of membrane glycoproteins (II, V)
Citrated blood samples from patients were analyzed within 3 h of blood sampling. 
The analyses were made from PRP (II) or whole blood (V).
In PRP analyses the samples were handled the same way as in the 
immunofl uorescence test (6.2.12), except that the fi xation was performed 
immediately after PRP separation and the fi nal cell concentration was 100x109/
l. In the direct method, platelets were incubated for 30 min at 37°C with FITC-
conjugated monoclonal antibodies against GPIbα (CD42b, SZ2, Immunotech S.A., 
Marseilles, FR), GPIIb-IIIa (CD41a, P2, Immunotech S.A, US), and GPIb-IX complex 
(CD42a, Immunotech S.A., US). FITC-conjugated non-specifi c IgG (MOPC-21, MG 
101, Caltag Laboratories, Burlingame, CA, US) was used as a negative control. 
For indirect measurement of GPIX, GPV, and GPIbβ in PRP, platelets were fi rst 
incubated for 30 min at 37°C with unlabeled antibodies (CD42a, FMC-25, Silenus, 
Victoria, Australia; CD42d, SW16, CLB, Amsterdam, NL, and CD42c, Gi27, a 
generous gift from Dr Santoso, Justus Liebig University Giessen, DE; respectively). 
FITC-conjugated anti-mouse antibody (Dacopatts, Glostrup, DK) was applied as 
the secondary antibody. The analyses were performed using a fl ow cytometer 
(FACScan, Becton Dickinson, San Jose, CA, US). A fl uorescence histogram was 
obtained by analyzing the data of 2000 ungated events vith a software program 
(LYSYS II, Becton Dickinson, San Jose, CA, US). From platelets of patients and 
controls, the platelets of similar size were gated for the analysis to avoid the 
infl uence of varying size of platelets on the detection of glycoproteins. The levels 
of expression were estimated by measuring the discrepancy between the overlaid 
histograms from platelets of a given patient and her control.
In the whole blood analysis, 20 µL of blood was incubated for 20 min at 37°C 
with 20 µL CD41-PE (CD41, P2, PN IM1416, Beckman Coulter/Immunotech, 
Beckman Coulter, Inc., Fullerton CA, US), and with 10 µL of FITC-conjugated 
monoclonal antibodies against GPIb (CD42b, SZ2, P42648F, Biodesign, Maine, 
US), GPIIb-IIIa (CD41, CLB-tromb/7, 6C9, M 1674, CLB, Amsterdam, NL), and 
GPIb-IX (CD42a, SZ1, N42538F, Biodesign, Maine, US), separately. The analyses 
were performed using a fl ow cytometer (FACScan and Cell Quest program, Becton 
Dickinson, San Jose, CA, US). The platelets were gated from the FSC/PE dot plot. 
Five thousand events were acquired to the platelet gate, which was approximately 
1.0-1.5 x107 cells altogether. The MFI of GPs was recorded from histograms.
7.2.11 Platelet autoantibodies (IV, V) 
Measurement of PA-IgG
PA-IgG analysis was performed according to the method described in detail 
elsewhere 248. Blood samples from thrombocytopenic patients (3 x 10 ml of EDTA 
blood) were sent either by overnight transportation (IV) or within one hour from 
sampling (V). Platelets were centrifuged at 350 x g for 10 min, PRP was isolated, 
and washed two times with washing buffer (Na2HPO4 x 2H2O 0.0176 mol/l, Na2-
EDTA x 2H2O 0.0089 mol/l, NaCl 0.1540 mol/l, NaN3 0.02 %, pH 6.8–7.2, bovine 
serum albumin 1%) followed by centrifugation at 1600 x g for 15 min. Platelets 
were fi xed with 1% formaldehyde and washed once more with washing buffer. The 
platelet concentration was adjusted to 500x109/l. 
50 µl of platelet suspension was incubated with 50 µl of 1:10 diluted FITC-
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conjugated rabbit anti-human IgG (Anti-IgG, F123, 2,4 g/L, Dacopatts Glostrup, 
DK) on bovine serum albumin coated micro titer plates for 30 min at 37°C. After 
incubation, the platelets were washed with washing buffer, and suspended in 500 
µl of buffer.
The analyses were performed using a fl ow cytometer (FACScan, Becton 
Dickinson, San Jose, CA, US). To enable analysis of thrombocytopenic samples, no 
more than fi ve thousand events were acquired from each sample. The gate was set 
to obtain 99% of events with a typical dot plot of platelets (FSC vs. SSC) according 
to the healthy control sample, if necessary. The mean FSC and mean fl uorescence 
intensity (MFI) of PA-IgG were recorded. 
Controls. The preanalytical factors were covered by the use of controls, which 
were handled in the same way as patient samples to minimize the infl uence of, 
e.g. whole blood storage prior to preparation249, EDTA250-253, and fi xation with 
formaldehyde254. The infl uence of preventive maintenance of fl ow cytometry on the 
precision of the assay was minimized by repeating the analysis of the controls and 
at least 10 patient samples before and after maintenance. If the results differed 
systematically by more than 3%, the parameter settings were adjusted to achieve 
identical results. The settings had to be adjusted slightly three times during the 
fi ve years. 
For the follow-up of stability of the PA-IgG measurement, control results were 
analyzed from fi ve consecutive years (1999-2003). 
Five control samples were included in each series: two commercial control 
samples (unlabeled and labeled beads, CaliBrate 349502, Becton Dickinson, 
San Jose, CA, US), one sample from a healthy donor, and two sensitized platelet 
controls (a strong positive and a cut-off control). 
Unlabeled and FITC-labeled beads were used to control the stability of the fl ow 
cytometry. The same batch was used for no longer than eight months. 
A sample from a random healthy donor was used as a control to check all 
steps of analysis, as reference for platelet light scatter properties, and to follow 
the stability of the cut-off level. The sample was drawn 24 h before analysis and 
processed as for the patient samples. The cut-off value of positive PA-IgG was 
calculated yearly from the mean of donor samples (mean+2s; yearly means varied 
from 300 to 309 MFI). 
A strong positive control was used to monitor the linearity and stability of the 
measurement at high levels of PA-IgG. It controlled the analysis from the step 
of labeling of the platelets to the measurement. The control was prepared by 
incubating a pooled platelet preparation from six blood group O donors with 1:2 
diluted serum containing strong anti-HPA-1a antibodies. The dilution level of anti-
HPA-1a serum was chosen so that the PA-IgG result of the control would be as high 
as possible but still within the linear region of the fl uorescence (data not shown). 
The same batch was used for up to one year.
A cut-off (positive) control was used to monitor the linearity and stability of the 
measurement at cut-off level. In the analysis this controlled the step from labeling 
of platelets to the measurement. The control was prepared by incubating a pooled 
platelet preparation from six blood group O donors with 1:64 dilution of the same 
serum as for the strong positive control. The same batch was used for up to one 
year. 
A new batch of all controls in the same series was compared to the previous 
batch for three-to-fi ve times to establish new target values. Only one control was 
changed at a time.
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GP-specifi city of platelet autoantibodies
Specifi city of PA-IgG was measured by direct MAIPA as described originally by 
Kiefel et al 255 and more recently by Joutsi-Korhonen et al57. 25 µl of thawed platelet 
suspension of 1000x109/l was incubated in a single tube for 30 min at 37°C with 
0.2 µg of two monoclonal antibodies, one specifi c for the GPIbα (AP1) and the other 
specifi c for the GPIIb-IIIa (AP2) (both generous gifts from Doctors Kunicki and 
Montgomery, Blood Center of Southeastern Wisconsin, Milwaukee, WI, USA). In 
the measurement of GPV-specifi c antibodies, 80 µl of thawed platelet suspension 
of 1000x109/l was incubated with 0.2 µg of monoclonal antibody specifi c for GPV 
(SW16 CLB, NL). The cells were washed three times with isotonic sodium chloride, 
and thereafter solubilized in cold TBS buffer (0.01 M trishydroksimethylaminome
thane, 0.5% Nonidet P40, 0.9% sodiumchloride, 2% Leupeptin). 50 µl aliquots of 
the supernatant were added to a 100 µl of buffer (0.01 M trishydroksimethylamino
methane, 0.58 mM calciumchloridehydrate, 0.5% Nonidet P40, 0.05% TweenR 20, 
0.9% sodiumchloride) and kept refrigerated overnight. 70 µl of the solution was 
incubated in anti-mouse IgG precoated micro wells in triplicate. Prior to washing 
six times with TBS-buffer, the plates were kept refrigerated for 90 min. 100 µl of 
second antibody (Affi nipure goat anti-human IgG, Fc-specifi c, peroxidase labeled, 
Jackson 109-035-098, US) was refrigerated for two hours. Plates were washed 
six times with TBS-buffer. 100 µl of 1,2-phenylene-diamine substrate was added, 
and the plate was incubated at 37 °C for 30 min. The absorbances were measured 
at 492 nm with spectrophotometer and special software (Multiscan EX, Thermo 
Electron Corporation, Vantaa, FI). 
To enable inter- and intralaboratory comparisons, the absorbance values of 
patient samples were divided by the absorbance of a negative control in each test 
series205. A sample was considered to have increased GP-specifi c PA-IgG when the 
ratio was ≥2.0, and the antibody level was classifi ed as strong positive when the 
ratio was ≥4.0. Platelets with GPIIb-IIIa-specifi c PA-IgG (anti-HPA-1a sensitized 
platelets) and platelets with increased GPV-specifi c PA-IgG 57 were used as controls. 
The expression level of different GPs was taken into consideration in the amount 
of platelets used for a single test.
7.2.12  Other analyses 
Metabolic parameters (pH, pO2, pCO2, lactate, and glucose) were measured with a 
blood gas analyzer (ABL 705, Radiometer Medical A/S, Denmark) at 37°C.
The non-reduced proteins from platelet lysates were separated by 7.5% SDS 
polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane 
(BioRad, CA, US)  by electroblotting as described in detail elsewhere256. After 
blocking in 0.5% Tween 20 and two washes the proteins were visualized with 
monoclonal antibodies against GPs Ib and IX (SZ2 Immunotech, FR and FMC-25 
Silenus, AUS). Alkaline phosphatase labeled goat anti-mouse IgG (Immunotech 
S.A., FR) was used as the secondary antibody.  
7.3  Quality assurance of methods
Westgard multirule quality control rules 13s, 22s, and 41s were applied to detect 
random and systematic errors in every measurement where there were controls 
available227. For every control, monthly means and standard deviations were 
calculated. Patient means were used for long-term follow-up of stability. In the 
validation of the methods, uncertainty of the results was calculated using the 
equation:
22 )assay-inter()assay-intra(2(%) CVCVU ???
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Although preanalytical factors are often the most important factors infl uencing the 
uncertainty of the assay, they were not included in the calculation of uncertainty. 
They were only taken into account by handling the control samples the same way 
as the patient samples.
7.4 Statistics
Data were analyzed using Statistica (StatSoft, Tulsa, OK, US) (I,II), StatsDirect 
(version 1.8.10; StatsDirect Ltd, UK) (IV,VI), and SPSS 7.5 Software (SPSS, 
Chicago, IL, US) (III, VI). 
Results are expressed as mean values and 95% confi dence intervals (I-VI). 
Comparisons between groups were analyzed by the Student’s t-test for indepent 
samples (I), the Mann-Whitney U-test (II-VI), the two-tailed F-test (II), and 
the Kruskall-Wallis test (III). Medical history data was analyzed by the Yates 
Corrected Chi-square test (I). Correlations were analyzed by linear regression 
and Spearman’s rank correlation (III, V). The mean, standard deviation (SD), 
coeffi cient of variation (CV), and skewness of distribution were calculated (IV). The 
correlations between methods, R², and the signifi cance of R were calculated with 
multiple linear regression tests from results (IV), and from indication-corrected 
results (VI). The paired t test with Bonferroni correction was used to calculate 
differences between groups (VI).
In all studies, P-values below 0.05 were considered statistically signifi cant.
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8 RESULTS
8.1 Repeatability and reference values of methods (I-VI) 
The intra- and interassay variations, uncertainty of methods, and reference values 
whenever they were measured, are presented in Tables 6 and 7.
Method Measuring 
range
Control* Level Intra-
assay cv,
%*
Inter-
assay cv,
%* 
Un-
certainty 
%
Reference 
range/cut-
off value*
Platelet count 0-1300 Whole blood 20 10 9.3 27 145-335
(x109/l; hydrodynamic focusing) Whole blood 200 3.9 4.3 12
PRP 900 0.3 0.4 1.0
Platelet size 5-20 Whole blood 7 1.8 2.2 6 8-12
(fl; hydrodynamic focusing) Whole blood 12 2.1 2.3 6
Whole blood 20 1.9 2.5 6
Platelet size 250-580 Healthy control 350 1.9 3.4 8 309-376
(FSC; flow cytometry) Patient PLTs 430 0.4 0.6 1
Thrombopoietin (pg/ml) 0-200 Commercial 7.0 17 7.0 37 6-70
Healthy control 20 5.0 15 32
Commercial 150 5.0 5.0 14
Reticulated platelets (%) 0-100 Healthy control 1.6 9.3 16 36 <10
Membrane GP Ib (MFI) Healthy control 330 2.2 8.0 17 >350
GP IIbIIIa/IbIX-specific platelet 0.5-30 Healthy control 1.0 2.5 5.3 12 <2
 associated IgG (ratio) Sensitized PLTs 9.0 5.8 12 27
GP V-specific platelet 0.5-30 Healthy control 1.0 2.1 4.5 10 <2
associated IgG (ratio) Patient PLTs 5.0 5.1 12 25
Platelet associated IgG (MFI) 210-701 Healthy control 230 2.3 4.5 10 <300
Sensitized PLTs 600 0.7 1.6 4
Shape change (D, %) 3-15
     ADP (3mg/ml) Healthy control 5.0 15 20 50 <7
     Arachidonic acid (1.2mg/ml) Healthy control 5.0 8.9 10 27 <7
     Collagen (0.42mg/ml) Healthy control 5.0 9.3 11 29 <8
Shape change (T, sec) 15-91
     ADP (3mg/ml) Healthy control 15 9.1 13 31 19-23
     Arachidonic acid (1.2mg/ml) Healthy control 15 8.3 15 34 21-42
     Collagen (0.42mg/ml) Healthy control 15 8.2 10 26 44-74
Swirling (scored by naked eye) 1-4 - - - 4
Extent of shape change (%) 5-20 PC 15 7.4 10 25 -
Hypothonic shock reaction (%) 20-70 PC 30 6.5 11 25 -
Soluble GPV (ng/l) 5-280 PC supernatant 57 3.0 5.5 9.0 55-216
PC supernatant 134 2.0 3.2 7.5
Soluble GPV (pmol/10
9
 platelets) PC <23.2#
CD62P (%) 5-50 PC 30 2.4 6.8 14 -
CD63 (%) 70-95 PC 70 3.7 11 24 -
pH 6-8 PC 7.0 - 0.03 0.1 6.4-7.4
#
pO2 (mmHg) 50-80 PC 70 - 1.5 3.0 -
pCO2 (mmHg) 20-50 PC 30 - 0.8 1.6 -
Glucose (mmol/l 2-10 PC 8.0 - 1.5 3.0 -
Lactate mmol/l 2-6 PC 2.0 - 2.2 4.4 -
* for N, see Table 5, Chapter 7.1.2         # for platelet concentrates
Table 6. Repeatability, uncertainty, measuring range, and reference values of 
methods. 
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8.2 Platelet count and size (I-VI) 
Platelet count. The results obtained by instruments using impedance and 
hydrodynamic focusing principles, correlated well (Figure 7, R=0.997, range 20-
980 x 109/l, n=52). 
Platelet size measured by cell counter and fl ow cytometry. Platelet size measured 
by the impedance detection method also correlated well with that measured by 
the hydrodynamic focusing principle (Figure 8A) and with the mean channel values 
of FSC in fl ow cytometry (Figure 8B; R=0.97 and 0.83, respectively, range 8-21 
fl , n=25). The FSC means of controls from several years did not differ statistically 
when compared with the target value of the control (paired t test, p>0.999; Table 
8).
Method Intra-
assay 
cv % 
Inter-
assay 
cv % 
Un-
certainty 
%
Reference 
range/cut-
off value
Intra-
assay 
cv % 
Inter-
assay 
cv % 
Un-
certainty 
%
Reference 
range/cut-off
value
     ADP (1mg/ml) 49-72 62-81
     ADP (3mg/ml) 8.3 6.4 21 69-85 3.3 4.3 11 77-90
     ADP (6mg/ml) 84-90 83-97
     Arachidonic acid (1.2mg/ml) 5.3 1.4 11 78-96 2.7 4.4 10 74-99
     Ristocetin (0.75mg/ml) <8 <3
     Ristocetin (1.25mg/ml) 2.7 1.3 6.0 79-92 0.8 1.1 3 35-52
     Ristocetin (1.50mg/ml) 89-93 54-68
     Adrenalin (0.9mg/ml, step 1) 18-87 17-34
     Adrenalin (0.9mg/ml, step 2) >70 20-31
     Adrenalin (9mg/ml, step 1) 8.7 16 36 19-28 5.3 13 28 21-34
     Adrenalin (9mg/ml, step 2) >70 20-34
     Adrenalin (54mg/ml, step 1) 16-26 19-34
     Adrenalin (54mg/ml, step 2) >60 18-30
     Collagen (0.42mg/ml) 4.3 3.4 11 61-85 2.3 4.2 10 45-67
     Collagen (0.84mg/ml) 80-92 65-82
Spontaneous 6-9 -
For measurement of uncertainty, N=6, and for reference values N=20
Aggregation maximy (Amax, %) Aggregation velocity (AV, %/min)
Figure 7. Platelet count measured by two 
different measuring principles (impedance 
and hydrodynamic focusing). The PRP of 
a patient sample (1000x109/l) was diluted 
with platelet poor plasma (1/50-1/1.02). 
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Table 7. Repeatability, uncertainty, and reference values for maximal aggregation 
and velocity of aggregation method. The measuring range was 0-100%. 
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Year N Donor Cut-off 
control
Positive 
control
Beads
1 10 366±18.4* - 351±8.0 666±9.2
2 11 343±14.3 364±2.0 354±4.1 656±0.5
3 12 334±11.9 344±4.4 334±3.9 601±1.3
4 10 369±14.6 377±5.0 376±4.2 636±6.5
5 11 342±11.2 365±4.6 354±6.4 619±1.5
* mean±SD
 
 
Platelet count and size in FAF patients did not differ from those of the siblings 
nor the healthy controls (I). As expected, platelet counts of seven BSS patients 
were signifi cantly decreased. Platelet size measured both as MPV and FSC, was 
dramatically increased compared to healthy controls (unpublished data) (II). The 
distribution of mean platelet size (FSC) of 854 patients studied for suspected 
autoimmune TP differed signifi cantly from that of healthy control samples (IV). 
Platelet count and size of 19 children with chronic TP differed statistically from 
those of healthy controls (Table 9). Platelet size was indirectly correlated with the 
platelet counts of the patients (Figure 9) (V).  
Platelet count in cord blood varied from 10 to 30x109/l in HPA-1a immunization, 
from 120 to 210x109/l in HPA-5b immunization, and from 200 to 380x109/l in 
newborn control samples. (III). 
 In platelet products, platelet count and size did not change signifi cantly during 
transportation. Platelet size was increased (n=5) when the swirling of platelets 
was at level 3 (VI). 
Figure 8. Platelet size measured by the impedance method (A, B), the hydrodynamic 
focusing method (A), and fl ow cytometry (B) (n=25). 
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Table 8. Stability of controls for FSC. Control means did not differ statistically 
from the target values. Control lots changed in each analysis.
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8.3 Thrombopoietin and reticulated platelets (III,V)
By strict validation of the TPO method, the lower limit of detection could be 
extended from 25 to 7 pg/ml.  
TPO in cord blood plasma of 15 fetuses correlated inversely with the platelet count 
(R=-0.53, p=0.006). TPO in cord blood at term was higher in HPA incompatibility, 
HPA-5 alloimmunization, and HPA-1a alloimmunization than that of adult and 
newborn controls (130, 115, and 170, vs. 28, and 76 pg/ml, respectively).  At 
term, TPO in amniotic fl uid (7 pg/ml; 0-22 pg/ml) was signifi cantly lower than in 
simultaneous cord plasma samples (114 pg/ml; 43-201 pg/ml; p<0.001). There 
Figure 9. Association of platelet 
count and size in 19 children 
with chronic TP
Table 9. Patient platelet counts and size compared to those of healthy controls or 
siblings.
Patients/samples n Reference
range  (x 
10
9
/l) p*
range 
(fl/FSC) p*
FAF I
 - patients 20 123-224 7-9
 - healthy siblings 10 122-224 0.87 8-9 0.86
 - healthy controls 20 129-275 0.10 7-9 0.24
BSS II
 - patients (size as MPV) 7 43-81 13-17
 - healthy controls (size as MPV) 10 146-311 <0.0001 8-10 <0.0001
 - patients (size as FSC) 369-478
 - healthy controls (size as FSC) 10 310-346 <0.0001
Thrombocytopenic patients
 - patients (size as FSC) 854 - 268-523 IV
 - healthy controls (size as FSC) 112 - 308-402 <0.0001
Chronic TP of childhood V
 - patients 19 58-292 8-15
 - healthy controls, children 6 161-249 0.0032 8-10 0.0490
 - healthy controls, adults 14 145-296 0.0004 7-9 0.0041
*difference between patients and healthy controls/siblings
Plt count Plt size
R = -0.763
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was no correlation between levels of TPO in amniotic fl uid or cord plasma and 
platelet counts. In fi ve fetuses with HPA-1a alloimmunization, the TPO levels in 
amniotic fl uid were signifi cantly higher than at term, correlating inversely with 
gestational age (R=-0.91, p=0.003). (III)
In the 19 children with chronic TP, TPO levels measured from EDTA samples (41 
pg/ml; 1-213  pg/ml) were signifi cantly higher than those in the plasma of healthy 
children or adult controls (14 pg/ml, 1-29 pg/ml, and 17 pg/ml, 1-25 pg/ml; 
respectively) (p=0.032 and 0.0038, respectively). Increased megakaryocytosis at 
diagnosis was not associated with the TPO concentration. (V)
RPs of a given healthy control varied from 0.9 to 1.9%. In thrombocytopenic 
patients, %RP was signifi cantly higher than that in the plasma of healthy children 
or adult controls (p=0.003 and 0.0006, respectively). In all patients with platelet 
count lower than 50 x 109/l, %RP was remarkably high (9.1 vs. 2.2%, in healthy 
controls, p<0.0001). Increased megakarocytosis at diagnosis associated with 
higher %RP (p=0.03). There was a positive correlation between %RP and MPV 
(R=0.68, p=0.0007), and a negative correlation between %RP and TPO (R=-0.69, 
p=0.0006). (V)
8.4 Evaluation of platelet activation and function (I, VI)
8.4.1 Swirling (VI)
For the quality control of platelet products transported to induce hypoxic stress, 
twelve PC units were transported and twelve PC units served as controls. 
Morphology was evaluated on days 1, 3 or 4, and 5 or 6. Swirling score 3 was 
noticed in fi ve platelet products: four in the transported group (transported on day 
1 and day 5) and one platelet product before transportation (the score changed to 
4 during transportation).
8.4.2 Extent of shape change and hypotonic shock reaction (VI)
In platelet products stressed or non-stressed by transportation (Figure 10), ESC 
decreased signifi cantly from day 1 to day 6, if the platelet products were transported 
on days 1 and 5 (p=0.028). On day 6, there was no signifi cant difference between 
results.
When the transportation was performed on days 3 and 4, ESC differed 
statistically between Days 3 and 6 in platelet products without or with transportation 
(p=0.0015 and 0.028, respectively). Again, on day 6, there was no signifi cant 
difference between results.
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Figure 10. Extent of shape change of six platelet products with or without 
transportation stress as a function of storage time (mean±1SD).
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In platelet products either stressed or non-stressed by transportation, HSR 
decreased linearly during storage (p=0.012). On day 6, there was no signifi cant 
difference between the responses. In general, the responses resembled the 
changes in ESC (Figure 10).
8.4.3 Platelet shape change (I) and aggregation test in PRP (I, II)
In FAF patients, the D and T values were measured after stimulation of platelets 
with ADP (2.3, 7.0, and 14 µmol/l). Shape change was slower and increased 
as compared to the healthy siblings and controls. When patients and unrelated 
controls were compared, the D value was signifi cantly increased after 2.3 µmol/l 
ADP induction and the T value signifi cantly increased after 2.3, 7.0, and 14 µmol/l 
ADP induction.
Platelet shape change was not quantifi ed in the BSS patients due to low platelet 
count.
The aggregation of platelet “rich” plasma of BSS patients could only be studied 
using ADP and ristocetin as agonists, because of small platelet concentration in 
the sample. Aggregation was considered  normal in response to ADP and absent or 
greatly reduced in response to ristocetin. 
In FAF patients, both maximum aggregation and maximum velocity were 
measured with ADP, aracidonic acid, ristosetin, adrenalin, and collagen stimulation 
and at spontaneous aggregation. There were no signifi cant differences in patients 
compared to reference values except in the maximal velocities after the lowest 
ristocetin and the strongest adrenalin stimulation as well as after arachidonic acid 
stimulation (p<0.050, when compared with healthy siblings, and p<0.005 when 
compared with healthy controls).  
8.4.4 Expression of activation markers CD62P and CD63 on platelets (VI)
Expression of CD62P: The maximal CD62P expression after thrombin activation 
was 82%. The expression of CD62P increased signifi cantly between days 1 and 6 
regardless of transportation stress (p<0.0001). On day 6, there was no signifi cant 
difference between results in any groups (Figure 11). In general, the differences 
were parallel to the alterations in soluble GPV (Figure 12).
Expression of CD63: The maximal CD63 expression after thrombin activation 
was 98%. The expression of CD63 increased signifi cantly between days 1 and 6 
Figure 11. Expression of CD62P of six platelet products with or without transportation 
stress as a function of time (mean±1SD).
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regardless of transportation stress (p<0.005). On day 6, there was no signifi cant 
difference between the groups.
8.4.5  Soluble GPV as platelet activation marker (VI)
The maximal soluble GPV concentration after thrombin activation was 23.2 pmol/
109platelets.
The soluble GPV increased close to maximum during storage whether the 
platelet products were stressed or not (p<0.001). On day 6, there was no 
signifi cant difference between results in any groups (Figure 12).
The precision of the methods (intra- and inter-assay CVs) of all tests was 
good. The best correlations were between soluble GPV, CD62P, CD63, lactate, and 
glucose (p<0.0001) (Table 10). There was a weaker correlation between soluble 
GPV, ESC, HSR, CD62P, CD63, lactate, and glucose (p<0.093). pH correlated only 
with pCO2.  
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Figure 12. Soluble GPV of six platelet products with or without transportation 
stress as a function of storage time (mean±1SD).
( )
HSR sGPV CD 62P CD 63 Lactate Glucose pO2 pCO2 pH
ESC 0.56 -0.56 -0.57 -0.57 -0.56 0.55 -0.34 -0.08 0.27
HSR - -0.39 -0.64 -0.48 -0.54 0.51 -0.42 0.01 0.21
sGPV - - 0.95 0.82 0.86 -0.85 0.37 0.12 -0.37
CD 62P - - - 0.82 0.87 -0.81 0.47 0.16 -0.36
CD 63 - - - - 0.83 -0.81 0.34 0.16 -0.38
Lactate - - - - - -0.97 0.40 0.13 -0.44
Glucose - - - - - - -0.36 -0.10 0.47
pO2 - - - - - - - 0.25 -0.30
pCO2 - - - - - - - - -0.88
Table 10. Correlations (R) of results from different tests
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8.6 Platelet autoantibodies (IV, V)
The linearity of the PA-IgG method, studied with platelets incubated with anti-HPA-
1a antibodies, which was diluted in 1/2-1/256, proved to be excellent (Figure 13, 
R=0.998).
The PA-IgG means of controls did not differ statistically during several years 
when compared to the target value of each control (paired t test, p>0.999; Table 
12) 
The long-term stability of the method was also good when studied by means of 
consecutive patient results (Figure 14). 
Patient samples differed statistically from healthy controls in regard to platelet 
size and PA-IgG results (p<0.0001).
In patient samples grouped by platelet size, PA-IgG values were statistically 
higher in the group with either small (FSC mean±SD, 295±16, n=5) or large 
(403±25, n=292) platelets, compared to that with normal sized platelets (353±14, 
n=557) (p<0.0001).
Glycoprotein-specifi city of platelet-associated autoantibodies
GPIIb-IIIa/Ib-IX-specifi c antibodies were detected in 22% and GPV-specifi c in 13% 
of the PA-IgG positive samples, where there were enough platelets to perform the 
assay (Figure 15). Nineteen of 44 patients with GPIIb-IIIa/Ib-IX-specifi c PA-IgG 
had no GPV-specifi c PA-IgG, whereas fi ve of 25 patients with GPV-specifi c PA-IgG 
had no GPIIb-IIIa/Ib-IX-specifi c PA-IgG. 
Presence of GPIIb-IIIa/Ib-IX-specifi c antibodies was associated with PA-IgG 
(R=0.77; Figure 16). GPV-specifi c antibodies were also associated with PA-IgG 
(R=0.409, data not shown).
The historical platelet nadir recorded in the referrals of the 27 of 44 patients 
with GP-specifi c PA-IgG displayed negative correlation with the level of GPIIbIIIa 
and/or IbIX-specifi c PA-IgG (R=-0.544, Figure 17). 
( )
Isotype 
control
CD 41a* CD 42a* CD 42b*
Healthy 
control Patient 10
Mean (MFI) 260 475 441 330 353 88
CV (%) 6.5 3.6 5.8 4.9 3.8 3.4
* after reduction of background staining by isotype control
Healthy control CD 42b*
Table 11. Expression of platelet GPIIb-IIIa (CD41a), Ib-IX (CD42a), and Ib 
(CD42b). The control sample from a healthy donor was different in each series 
(n=114).
8.5  Defects of GPIb-IX-V expression in BSS (II, IV)
Long-term means and coeffi cients of variation of healthy controls and propositus 
10 (repeated samples, n=5) are presented in Table 11.  The control results cover 
six consecutive years. 
In the BSS patients with Asn45Ser mutation, the expression of GPIb and GPIb-
IX was markedly reduced as measured by the direct immunofl uoresence test. 
GPIX and GPV were moderately reduced in the indirect test, while GPIIb-IIIa was 
increased.
In chronic TP of childhood, membrane glycoproteins were measured from whole 
blood. No BSS was diagnosed among this patient population (n=21).
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Figure 13. Linearity of PA-IgG method 
measured with platelets incubated 
with diluted anti-HPA-1a antibodies. 
Table 12. Stability of controls for PA-IgG. The 
control lots changed in each follow-up period.
Figure 14. Patient means of 20 (*) and 200 (**) consecutive results and the 
accumulated means (***) of all samples sent for PA-IgG measurement during fi ve 
years.
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2 11 225±45.5 285±3.2 593±2.3 217±3.7 779±3.0
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Figure 15. Distribution of consequent patient samples according 
to screening for platelet-associated IgG (PA-IgG) and results of 
further determination of GP-specifi city of PA-IgG.
Figure 17. Platelet nadir 
in patients with GPIIbIIIa- 
and/or GPV-specifi c 
autoantibodies (n=27).
Figure 16. The association 
of GPIIbIIIa/IbIX-specifi c 
antibodies and PA-IgG (N=49; 
(o). In addition, GPV-specifi c 
PA-IgG was found in fi ve 
samples without GPIIbIIIa 
and/or IbIX-specifi city (□).
Samples recieved
N=854
PA-IgG negative
N=559
PA-IgG positive
N=295
GPIIbIIIa/IbIX and/or 
GPV-specificity negative 
N=157
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N=49
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to measure GP specificity 
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R = 0.769
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9 DISCUSSION
9.1 Quality of the assays (I-VI)
Preanalytical factors, such as medication of patients and lipemic plasma, are 
often the most important factors contributing to the uncertainty of an assay. In 
the present study, the preanalytical factors were considered, e.g. by formulating 
strict sample collection procedures. Moreover, the samples of healthy controls and 
siblings were handled in the same way as the patient samples. 
Because national and international quality control surveys are available only 
for platelet count, platelet volume, and blood gas measurements, the validity of 
the results was to be demonstrated by an exhaustive quality control program. In 
addition, commercial controls were available for platelet count, platelet volume, 
blood gas measurements, TPO, and soluble GPV assays.  It was possible to 
prepare long-term control samples for the qualitative tests used in this study, 
except for ESC, HSR, CD62P, CD63, and swirling measurements. The stability of 
the sensitized platelet controls has been reported to be seven days at 4°C and at 
least three months at -70°C257.  In the present study, the controls demonstrated 
stability over 12 months at 4°C. For the MAIPA measurement, the controls were 
stored frozen (-70°C) and have been stabile for at least four years. Published data 
on quality control of platelet antibody assays is scarce.
One of the advantages of quantitative assays is that methods are well 
standardized and interlaboratory comparisons possible. 
The intra-assay CVs were measured during validation of the tests and were 
checked monthly or bimonthly, and yearly. The inter-assay CVs were followed 
daily. Quality control by Westgard rules227, as applied in this study, proved to be 
useful also in qualitative allo- and autoantibody measurements. Follow-up with 
this kind of qualitative controls has not been presented elsewhere, although it has 
been recommended228. The use of patient means has been recommended as a 
long-term quality control of hematological assays258. In the present study, it was 
also shown to be applicable to platelet antibody assays. Bull’s moving averages 
of patient means were also used successfully for quality assurance as an easily 
applicable method. 
9.2 Platelet size (II, IV, V)
Mean platelet volume obtained by hematology cell counter may refl ect variations 
in the level of platelet stimulation, rate of platelet production, or platelet kinetics 
in general. As platelets are heterogeneous by age in the circulation, platelet size 
varies from time to time and during disease processes116. Because MPV is dependent 
on a number of variables, including interindividual differences, time to analysis 
after venepuncture, method of analysis, anticoagulant, and specimen storage 
temperature109, establishment of internal reference values in each laboratory is 
required. 
Platelet size measured by fl ow cytometry, using the hydrodynamic focusing 
detection principle and laser optics, gives an estimate of size even in severe TP. 
In the present study (IV), platelets were centrifuged and washed three times and 
they were also fi xed with formaldehyde before measuring, so the size might have 
changed. However, every series included a healthy control sample which was 
handled the same way as patient samples, and a reference range was determined 
from the results. 
The best sample medium would be fresh whole blood. In this study, MPV was 
directly associated with increased megakaryocytosis at diagnosis of chronic TP of 
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childhood. It has been recognized that the application of MPV as such needs further 
standardization108,109. In the future, monitoring of MPV, the platelet size distribution 
width (PDW) and platelet large cell ratio143, as well as the proportion of immature 
platelet fraction151 would give more information in thrombocytopenic patients.
It was observed, that GPIIb-IIIa/Ib-IX-specifi c antibodies correlated with PA-
IgG. The signifi cance of platelet size in quantifying GP-specifi c antibodies must 
also be evaluated separately in future studies.
Identifi cation of a thrombocytopenic patient with exceptional platelet size 
should be interpreted with great caution and lead to further diagnostic tests for 
syndromes, such as BSS, Gray platelet syndrome, May-Hegglin anomaly, and 
Wiscott-Aldrich syndrome. It should be observed that platelets may not always be 
giant in all BSS variants.  
Platelet size might also be a useful marker of quality of platelet concentrates. 
In platelet products, platelet count or size did not change statistically during 
transportation. Platelet size was greater when the morphology (swirling) of products 
was at level 3. This might have been caused by the formation of aggregates. A 
common calibration procedure designed specifi cally for the range of platelet counts 
in platelet products may be feasible, e.g. in comparisons of yields from different 
component separation processes between blood centers231.
Platelet size measurement both in thrombocytopenic patients and in platelet 
component production may be a useful marker and could be employed more often 
in analytics.
9.3 Reticulated platelets and thrombopoietin (III, V)
Similar to increased MPV, RPs indicate the stimulated production of bone marrow 
megakaryocytes. Standardization of the measurement of RPs is diffi cult because 
of the lack of a stable control. In this study, the RPs were gated conservatively 
according to the granularity of a single healthy control. To reduce inter-assay 
variation, the gating defi nitions were kept unchanged. The measurement of 
RP from whole blood by an assay where platelets are gated with a monoclonal 
platelet-specifi c antibody would prevent loss of largest young platelets inherent to 
the separation of platelets by centrifugation259,260. 
In children with chronic TP, patients with platelet counts <50x109/l at the 
time of the study had as a group remarkably increased %RP and increased 
megakaryocytosis at diagnosis. The fi ndings indicate that the origin of TP 
was peripheral destruction. Parallel results have been published from adult 
thrombocytopenic patients259,261,262. These results point to the value of adding %RP 
to the non-invasive clinical evaluation of TP. 
TPO is the major regulator of platelet production263. The clinical applicability 
of TPO measurement is somewhat controversial, although TPO is thought to be 
a good marker of TP264. The uncertainty about applicability possibly refl ects the 
delayed effects of TPO on peripheral counts160,263,265.
Nearly half of the children with chronic TP had TPO in the range of the 
controls while TP was still observed. This is in accordance with earlier results 
from pediatric TPs265. While there were patients whose high TPO was associated 
with low %RP, there were also patients whose low TPO was associated with high 
%RP. These fi ndings are most probably explained by the delayed effects. Within a 
pediatric patient population with chronic TP, in the clinical evaluation at least the 
measurement of %RP may be helpful for classifying the origin of TP as peripheral 
or central.  
By sensitizing the TPO measurement to the level of 7 pg/ml, it was possible to 
detect TPO also in amniotic fl uid. As suggested by gene expression levels266,267, and 
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later confi rmed268,269, TPO could be quantitated in umbilical blood plasma in fetuses 
considered to be at risk of fetomaternal alloimmune thrombocytopenia, and in 
healthy controls. In the present study, TPO levels in cord plasma were signifi cantly 
higher at term than in adult controls. TPO in amniotic fl uid was inversely related to 
gestational age in this test setting. Whether the TPO levels in amniotic fl uid were 
normal in pregnancy or whether they were associated with HPA-alloimmunization 
remained unclear.
9.4 Platelet shape change (I, VI)
The swirling phenomenon is a robust assay of platelet morphology in platelet 
concentrates performed by the naked eye. It is reportedly due to discoid platelets 
changing shape to spheres 270. As long as there is no other applicable quality 
test for screening of all PCs, swirling is included in everyday analysis of platelet 
components142.
In the quality control of PCs, inspection of swirling is the only measure that can 
routinely be used when a PC unit is released for transfusion. It is easy to perform 
but was not found as sensitive as other methods used. 
Gelsolin is required for physical platelet shape change271, e.g. in severing actin 
fi laments and is also important  in platelet apoptosis272. A slower and more profound 
platelet shape change in association with platelet aggregation studies was observed 
in the FAF (A Gel amyloidosis) patients with variant gelsolin than in their healthy 
siblings and the healthy control subjects. This might be associated with the altered 
fragmentation of the mutated gelsolin and further with the bleeding tendency in 
patients. A causal relationship was, however, not ascertained. Reduced plasticity of 
neural cell development has been reported in cells from FAF patients196. Although 
the experimental data on platelet shape change is accumulating181,273,274, there are 
further possibilities for analyzing quantitavely platelet shape change in various 
patient groups.
9.5 Membrane glycoproteins (II, V)
In the present study, the analyses of membrane GPs were performed on equal sized 
platelets (FSC 300-500) in BSS patients homozygous for Asn45Ser mutation and 
in healthy controls. The expression of GPIb and GPIb-IX was markedly reduced, 
and that of GPIX moderately reduced, as reported in separate studies on single 
families189-191. The expression of GPV on platelets of BSS patients has not been 
reported earlier.  
Among the children with chronic TP, statistically signifi cant differences in 
the expression of membrane GPIb-IX were not observed, and thus no BSS was 
diagnosed. 
Future measurements of expression of membrane GPs would be even more 
exact and require less sample volume if PRP and indirect staining could be replaced 
by whole blood and direct staining. 
9.6 Platelet autoantibodies (IV, V)
PA-IgG measurement has been considered unnecessary and even inappropriate 
for establishing the diagnosis of TP 211,275. Part of the problem could refl ect the 
variation of platelet size in thrombocytopenic patients and also the specifi city of 
the test used. There was no drift in long-term medians of platelet size (FSC) and 
PA-IgG results of controls and patients through consecutive years. Thus, fl ow 
cytometric measurement of PA-IgG can be considered as a quantitative test. 
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More attention has been recently given to the determination of platelet size. 
New methodological applications have been developed for this purpose, such as 
immature platelet fraction and platelet large cell ratio143. PA-IgG varied according 
to platelet size in both donor and patient samples in this study. Also, PA-IgG and 
platelet size differed signifi cantly in the two groups. The results suggest that 
PA-IgG should be evaluated only in relation to platelet size in thrombocytopenic 
patients, which has not yet been done.
The presence of GPIIb-IIIa/Ib-IX-specifi c antibodies was associated with PA-
IgG. GP-specifi city of PA-IgG is considered a more specifi c method than PA-IgG213. 
A weaker association was seen with the presence of GPV. The presence of GPIIb-
IIIa/Ib-IX-specifi c antibodies was negatively associated with the historical platelet 
nadir of each patient given in the referral. This association has not been presented 
before.
GP immobilization assays measured either by immunobead or MAIPA-assay 
produce similar or at least parallel results205,276. In a further application, fl ow 
cytometric immunobead assay has been reported to have high specifi city but 
relatively limited sensitivity71.
Leytin et al reported that the amount of GPIIb-IIIa per resting platelet 
increased with increasing platelet size but the density of GPIIb-IIIa (GPIIb-IIIa 
per surface area) on the platelet was the same for all sized populations241. As the 
platelet size seems to have signifi cance as well as the GP-specifi city of platelet 
autoantibodies, the results of these two assays could be combined for evaluation 
of thrombocytopenic patients. Further studies should also elucidate the role 
of antibodies in samples with increased PA-IgG but without any apparent GP-
specifi city, using current techniques applying detection of GPIIb-IIIa/Ib-IX only.
9.7  Platelet activation markers (VI)
Some of the platelet markers can be quantifi ed directly from platelets, and 
measure the remaining function. ESC and HSR are considered as the ‘gold 
standards’ for in vitro assays of platelet quality. They reportedly correlate with 
the in vivo recovery percentage of radio-labeled stored platelets277. Furthermore, 
CD62P and CD63 assays correlate with ESC and HSR. The correlation of CD62P 
expression with in vivo recovery of platelets is still controversial. All these markers 
need to be measured from platelets themselves, and are laborious, and diffi cult to 
standardize. 
The most commonly used platelet quality control assays have been metabolic 
tests, such as pH, pO2, pCO2, rate of lactate production, and oxygen consumption 
rate, which can all be analyzed from the storage medium. Soluble CD62P and 
glycocalicin have been suggested as applicable methods100. Soluble GPV, suggested 
to be involved in the fi rst steps of platelet activation by thrombin, may be an 
early marker of activation278. It correlated extremely well with ESC and CD62P 
expression in this study, and is easier to perform and automate than whole platelet 
assays. Soluble GPV compares well with the gold standard methods, and may 
prove a signifi cant predictor of platelet quality in concentrates for platelet recovery 
and survival. 
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10 CONCLUSIONS
This study was focused on the search for new analytical means to examine 
thrombocytopenic patients in general, fetuses with alloimmune TP, amyloidosis 
patients, and platelet concentrates. New methods were also included. Our results 
generated many new fi ndings which may well prove helpful and informative in 
daily analytics.  
It was assumed that AGel amyloidosis may cause dysfunction in platelets. 
However, maximum aggregation was normal in most patients. As a totally new 
fi nding, platelet shape change in amyloidosis patients was prolonged and profound. 
It was concluded that a gelsolin dependent mechanism may cause the altered 
shape change. However, it was not possible to exclude the possibility that amyloid 
fi brils themselves could have altered platelet shape change as the measurement 
was done from PRP. Quantitative analyses of platelet shape change have not been 
previously applied in the analytics of patient platelets, and the fi ndings of the 
present study suggest that platelet shape change analysis could be applied more 
widely. 
The expression of GPIbα-IX in platelets of BSS patients with Asn45Ser mutation 
was uniformly decreased under the detection limit in a patient population which 
was also internationally exceptionally large. Small quantities of GPIX and V were 
detectable when platelets of the same size were analyzed. In diagnostics it is 
necessary to use more than one method. In addition to classically applied platelet 
aggregation induced by ristocetin, quantifi cation of GPIb-IX-V expression can be 
used for confi rmation of BSS diagnosis, or genetic diagnostics, if available.
In fetuses with alloimmune TP, thrombopoietin levels in cord plasma were 
signifi cantly higher than in adult controls, supporting stimulated thrombopoiesis. 
By extending the standard curve of the TPO measurement, it was possible to detect 
the presence of low concentrations of TPO also in amniotic fl uid. TPO of amniotic 
fl uid decreased with the duration of gestation. 
It is known that platelets in immune TP are larger than normal. Platelet size, 
however, has not been utilized in analysis of autoantibodies. The presence of GPIIb-
IIIa/Ib-IX-specifi c antibodies and PA-IgG correlated directly with each other. 
Noninvasive methods such as the measurement of reticulated platelets, and 
also of thrombopoietin, may be of value in clinical evaluation of thrombocytopenic 
patients and may replace bone marrow examinations in some patients. 
The new platelet marker, soluble GPV, compared well with the other selected 
methods and may thus replace less reproducible measurements on activated 
platelets. Direct comparison of soluble GPV with in vivo platelet recovery and 
survival is needed.
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